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ABSTRACT 
 
IRE1α RNASE-DEPENDENT LIPID HOMEOSTASIS PROMOTES SURVIVAL IN MYC-
TRANSFORMED CANCERS 
Hong Xie 
M. Celeste Simon 
 
        Myc family activation is a primary oncogenic event in many human cancers; however, these 
transcription factors are difficult to inhibit pharmacologically, suggesting that Myc-dependent 
downstream effectors may be more tractable therapeutic targets. Here, I show that Myc 
overexpression induces endoplasmic reticulum (ER) stress and engages the IRE1α-XBP1 
pathway through multiple molecular mechanisms in a variety of c-Myc- and N-Myc-dependent 
cancers, e.g. Burkitt’s lymphoma and neuroblastoma. In particular, Myc-overexpressing cells 
require IRE1α-XBP1 signaling for sustained growth and survival in vitro and in vivo, dependent on 
elevated stearoyl-CoA-desaturase 1 (SCD1) activity. Pharmacological and genetic XBP1 
inhibition induces Myc-dependent apoptosis, which is alleviated by exogenous unsaturated fatty 
acids. Of note, SCD1 inhibition phenocopies IRE1α RNase activity suppression both in vitro and 
in vivo. Furthermore, IRE1α inhibition enhances the cytotoxic effects of standard chemotherapy 
drugs used to treat c-Myc-overexpressing Burkitt’s lymphoma, suggesting that inhibiting the 
IRE1α-XBP1 pathway is a useful general strategy for treatment of Myc-driven cancers.  
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CHAPTER 1: Introduction 
 
Introduction to Myc and its role in cancer 
 
        The Myc family of proto-oncogenes (MYC, MYCN, MYCL) encodes the c-Myc, N-Myc, and 
L-Myc basic helix-loop-helix leucine zipper (bHLHZ) transcription factors, respectively. Myc 
oncoproteins belong to a family of so-called “super-transcription factors” that potentially regulate 
the transcription of at least 15% of the entire genome (Dang et al., 2006). Upon activation, Myc 
recognizes CACGTG sequences termed “E boxes”, as a heterodimer paired with its binding 
partner Max, to regulate genes coordinating numerous cellular processes, including but not 
limited to proliferation, apoptosis, differentiation, self-renewal, and metabolism (Dang, 2013; 
2012).  
 
        MYC is the only isoform expressed ubiquitously in a broad range of tissues and organs. In 
contrast, MYCN and MYCL are expressed in a more tissue-restricted manner, such as in the 
central nervous system and lung epithelium (Dang, 2012). However, it is generally believed that 
Myc family members can sometimes be functionally interchangeable (Malynn et al., 2000). 
Although MYC genes are normally induced by mitogenic stimulation and their activity tightly 
regulated under physiological conditions, oncogenic activation occurring via mutation, genomic 
amplification, and translocation leads to aberrant overexpression or stabilization of Myc proteins 
(Gabay et al., 2014). 
 
        MYC is the most frequently amplified oncogene in human cancers (Beroukhim et al., 2010). 
It was first discovered as the cellular homolog of the retroviral v-Myc oncogene identified from 
studies of oncogenic retroviruses (Bister and Jansen, 1986; Duesberg et al., 1977; Sheiness et 
al., 1978). Afterwards, chromosomal translocations that juxtapose MYC to immunoglobulin 
enhancers were discovered in Burkitt’s lymphoma (BL) (Dalla-Favera et al., 1982). Classic in vitro 
assays using normal primary rat embryo fibroblasts then documented c-Myc’s transforming 
activity in cooperation with activated RAS and the sufficiency of these two oncogenes to 
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transform normal cells (Land et al., 1983). In addition, multiple transgenic mouse models based 
on deregulated c-Myc expression have illustrated its transforming activity in vivo and support the 
notion that it is a human oncogene (Morton and Sansom, 2013).   
 
Targeting oncogenic c-Myc as a strategy for cancer treatment 
 
        Dysregulation of Myc oncoproteins is a frequent event in a broad array of human cancers, 
including BL, breast cancer, neuroblastoma (NB), etc (Dang, 2012). The established role of c-Myc 
protein in tumor initiation and maintenance has made it an appealing target for cancer therapy 
(Gabay et al., 2014; Huang and Weiss, 2013; Schmitz et al., 2014). In the past two decades, 
numerous attempts have been made to develop strategies to directly or indirectly target c-Myc 
expression or activation (Brooks and Hurley, 2010; Delmore et al., 2011; Kiessling et al., 2007; 
Puissant et al., 2013). However, despite a confluence of detailed mechanistic insights and unmet 
medical needs, therapeutic strategies to directly manipulate c-Myc remain a historic challenge 
(McKeown and Bradner, 2014; Meyer and Penn, 2008). Therefore, essential steps involved in c-
Myc deregulation have been exploited as new approaches to treat c-Myc-driven cancers. 
Examples include targeting c-Myc transcription with BET inhibitor JQ1 in multiple types of cancers 
(Delmore et al., 2011; Puissant et al., 2013), targeting MYC mRNA translation using 
pharmacological inhibition of the PI3K/AKT/mTOR pathway (Bjornsti and Houghton, 2004; 
Chapuis et al., 2010; Frost et al., 2004; Yu et al., 2001), targeting c-Myc stability through the 
ubiquitin-proteasome system (Popov et al., 2007; Tavana et al., 2016; Yada et al., 2004), or 
disrupting the Myc-Max complex (Annibali et al., 2014; Berg et al., 2002; Wang et al., 2007). 
These compounds appear to have significant therapeutic value for cancers with high levels of c-
Myc activity, although some effects are c-Myc-independent. However, future advanced trials are 
needed to examine their efficiency and safety in humans.  
         
Oncogene activation and endoplasmic reticulum (ER) stress in cancer 
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        Cellular transformation into the malignant phenotype is characterized by hyperactivation of 
oncogenes leading to unregulated cell cycle progression and proliferation. In normal cells, 
metabolism is fine tuned to match oxygen, nutrient, and growth factor availability. However, in 
tumor cells, oncogenic transformation on one hand commits cancer cells to anabolic growth rates, 
but on the other hand generates metabolic stresses, which must be overcome to sustain survival 
and growth. The ER is the organelle in eukaryotic cells responsible for protein folding and 
transport, the disruption of which leads to accumulation of unfolded or misfolded proteins – a 
condition termed “ER stress”. In addition, ER is a principle site for membrane biogenesis and a 
major distribution “hub” for lipid trafficking to and from the cell (Jackson et al., 2016; Quon et al., 
2018). In particular, increased ER protein load requires expansion of ER membranes via lipid 
synthesis, a process that is particularly important under ER stress. In addition, disrupted ER lipid 
composition also impairs protein-folding capacity.  Therefore, the maintenance of ER functions by 
coordinating protein synthesis and lipid metabolism is necessary to support the high rates of 
anabolic metabolism required for tumor growth (Griffiths et al., 2013; Young et al., 2013).  
 
        A number of cell-intrinsic mechanisms contribute to cancer cell-specific induction of ER 
stress, such as the hyperactivation of mTORC1 due to deficiencies of the tumor suppressor 
tuberous sclerosis complex proteins (Tsc)-1 or Tsc2 (Saxton and Sabatini, 2017). Indeed, 
multiple studies demonstrated that heightened protein synthesis in mTORC1-activated cells 
induces ER stress (Clarke et al., 2014; Ozcan et al., 2008), which is further exacerbated by 
conditions of nutrient and O2 deprivation characteristic of solid tumor microenvironments 
(Ackerman and Simon, 2014; Young et al., 2013). Another example is c-Myc activation. Activated 
c-Myc upregulates genes involved in ribosome biogenesis, resulting in substantial enhancement 
of protein translation and protein content (van Riggelen et al., 2010). This effect is required for c-
Myc-mediated transformation, as haploinsufficiency of ribosomal gene L24 reduced protein 
synthesis rates and inhibited tumor progression in the Eµ-Myc model of B-cell lymphoma (Barna 
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et al., 2008). In addition, Hart et al. demonstrated that c-Myc activation increases ER protein load, 
therefore inducing ER stress (Hart et al., 2012).   
 
ER stress and the unfolded protein response (UPR) signaling 
 
        Upon encountering ER stress, cells activate a series of complementary adaptive 
mechanisms to cope with protein folding alterations, which together are known as the unfolded 
protein response (UPR) (Hetz, 2012). In mammalian cells, the UPR has evolved into a complex 
network of signaling events, mediated by the activation of at least three major stress sensors: 
inositol-requiring enzyme 1 (IRE1), activating transcription factor 6 (ATF6), and protein kinase R 
(PKR) like endoplasmic reticulum kinase (PERK) (Hetz, 2012). Each stress sensor engages 
unique mechanisms to impact distinct transcription factors, initiating a specific molecular 
response (Malhotra and Kaufman, 2007; Ron and Walter, 2007). This process transduces 
information concerning the protein-folding status in the ER lumen to the nucleus and cytosol to 
buffer fluctuations in unfolded protein load. The outcome of UPR activation involves attenuation of 
protein synthesis, increased protein folding and elevated protein degradative pathways. If these 
adaptive pathways cannot resolve ER stress, cells enter apoptosis (Wang and Kaufman, 2014). 
 
        Interestingly, PERK promotes an autophagic program that sustains cell viability and 
promotes tumor growth in c-Myc-overexpressing cells (Hart et al., 2012; Nagy et al., 2013). In 
contrast, a role for the IRE1 pathway in c-Myc-overexpressing cells, and its potential utility as a 
therapeutic target for c-Myc-driven cancers, has not been investigated. IRE1 is the only ER stress 
sensor conserved from yeast to mammals, and the mammalian genome encodes two isoforms, 
IRE1α and IRE1β. IRE1α is more ubiquitously expressed, whereas IRE1β is restricted to the 
epithelium of the gastrointestinal tract (Chen and Brandizzi, 2013). IRE1 proteins have an ER-
luminal sensor domain that recognizes unfolded proteins, as well as cytosolic kinase and 
endoribonuclease (RNase) domains that mediate responses through downstream effectors (See 
Figure 1A) (Chen and Brandizzi, 2013). Under conditions of ER stress, IRE1 is activated through 
5	
	
dimerization and autophosphorylation, and removes 26 nucleotides from unspliced X-Box Binding 
Protein 1 (XBP1u) mRNA to generate spliced XBP1 (XBP1s), producing a functional XBP1s 
transcription factor (Figure 1A) (Chen and Brandizzi, 2013).  XBP1s in turn regulates the 
expression of numerous genes, the protein products of which operate ER-associated degradation 
(ERAD), the entry of proteins into the ER and protein folding, among other functions (Acosta-
Alvear et al., 2007; Lee et al., 2003). XBP1s also modulates phospholipid synthesis, which is 
required for ER membrane expansion under ER stress (Hetz et al., 2011). In cancer settings, 
XBP1s has been demonstrated to promote tumor progression in triple-negative breast cancer 
(Chen et al., 2014) and multiple myeloma (Mimura et al., 2012), as well as chronic lymphocytic 
leukemia (Tang et al., 2014). Besides functioning through XBP1 splicing, the IRE1 RNase also 
selectively degrades ER-bound mRNAs to alleviate ER protein load, a process known as 
regulated inositol-requiring enzyme 1-dependent decay (RIDD) (Hollien et al., 2009).  
 
Summary 
        The central goal of this study was to identify synthetic lethal targets in Myc-overexpressing 
cells as an alternative strategy for the treatment of Myc-dependent cancers. We demonstrated 
that the IRE1α-XBP1 pathway is engaged in both c-Myc- and N-Myc-driven cancers, and that c-
Myc regulates this pathway through multiple molecular mechanisms: 1) directly activating ERN1, 
HSPA5, and XBP1 transcription, 2) stabilizing IRE1α protein, and 3) increasing ER protein load, 
thereby activating IRE1α RNase activity and promoting XBP1 splicing. Moreover, IRE1α-XBP1 
signaling induces stearoyl-CoA desaturase (SCD) transcription, which generates unsaturated 
lipids required for ER membrane homeostasis.  Pharmacological inhibition of IRE1α RNase 
activity or XBP1 depletion decreases growth and initiates apoptosis preferentially in Myc-
overexpressing cells in vitro and in vivo, and is reversed by exogenous unsaturated lipids. 
Treatment with a SCD inhibitor phenocopies the effects of IRE1α suppression on in vivo tumor 
growth. Finally, a highly selective IRE1α inhibitor (B-I09) exhibits synergistic effects with standard 
6	
	
of care (e.g. Doxorubicin) to treat c-Myc-transformed BL. Taken together, these findings reveal an 
essential mechanism whereby oncogene-driven anabolic metabolism engages homeostatic 
stress responses to promote tumor growth. Importantly, the use of IRE1α inhibitors (like B-I09) 
could improve treatment of both c-Myc- (e.g. BL) and N-Myc- (e.g. neuroblastoma) driven 
malignancies.  
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CHAPTER 2 Materials and Methods 
 
Cell Culture  
        Raji, Daudi, Ramos, EB-2, SK-N-AS, and BE2C cells were obtained from the American Type 
Culture Collection in 2016, and the Kelly cell line was obtained from Sigma Aldrich. MEC1, 
MEC2, and WaC3 cells were described previously (Kriss et al., 2012). 8498 cells were obtained 
from Dr. Alexander L. Kovalchuk (National Institute of Allergy and Infectious Disease, National 
Institute of Health, Rockville, MD, USA) and Dr. Herbert C. Morse III (National Institute of Allergy 
and Infectious Disease, National Institute of Health, Rockville, MD, USA). N-MycER SHEP cells 
were described previously (Ushmorov et al., 2008). Cells were cultured for a maximum of 6 
weeks before thawing fresh, early passage cells, and routinely confirmed to be Mycoplasma 
negative. Raji, Daudi, Ramos, EB-2, MEC1, MEC2, WaC3, P493, 8498, N-MycER SHEP, and 
Kelly cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 
2mM glutamine, and penicillin/streptomycin and cultured in 5% CO2 at 37 °C. SK-N-AS cells were 
cultured in DMEM supplemented with 15% FBS, 2mM glutamine, 1X non-essential amino acid 
(NEAA), and penicillin/streptomycin. BE2C cells were maintained in DMEM with 10% FBS, 4mM 
glutamine, and penicillin/streptomycin. During experimental conditions, FBS was decreased to 
5%, with other components unchanged. For lipid deprivation experiments, lipid concentration in 
the culture medium was achieved through the dilution of complete FBS into Delipidized FBS (cat. 
900-123, Gemini Bio-products) without changing other components. The P493 cells were derived 
from human peripheral blood B cells immortalized by an EBV genome that is complemented with 
an EBV nuclear antigen-estrogen receptor (EBNA2-ER) fusion protein and a tetracycline-
repressible c-Myc transgene. With tetracycline (0.1µg/mL) and beta-estradiol (1µM), which 
activates EBNA2-ER, the cells proliferate with induction of endogenous c-Myc by EBNA2, 
achieving a "Low Myc" state that is equivalent to EBV-immortalized B lymphocytes. With 
tetracycline alone, c-Myc is suppressed and a "No Myc" state is achieved. In the absence of 
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tetracycline and beta-estradiol, ectopic c-Myc is induced in a "High Myc" tumorigenic state that 
resembles human BL. In N-MycER SHEP cells, N-MycER activation was performed by treatment 
with 4-Hydroxytamoxifen (4-OHT) at 200nM.  
Reagents 
        B-I09 was described in a previous publication (Tang et al., 2014) . Tetracycline (cat. 87128), 
beta-estradiol (cat. E8875), cycloheximide (cat. C7698), tunicamycin (cat. T7765), fatty acid free 
BSA (cat. A8806), OA (cat. O3008), POA (cat. P9417), sodium palmitate (cat. P9767), 4-OHT 
(cat. H7904), doxorubicin hydrochloride (cat. D1515) were purchased from Sigma Aldrich. JQ1 
(cat. 4499) was from TOCRIS. 4µ8c (cat. 412512) was from Millipore. SCDi (cat. Cay10012562) 
and vincristine sulfate (cat. 11764) were purchased from Cayman. U-13C-glucose (cat. CLM-1396) 
was from Cambridge Isotope Laboratories.  
Plasmids, Virus production and Infection 
        GIPZ non-silencing lentiviral shRNA control (Clone ID:  RHS4346) and shRNA targeting 
XBP1 (Clone ID: V3LHS_387388) were purchased from Dharmacon. Inducible control shRNA 
(Forward: 5’-
CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTG-3’, 
reverse: 5’-
AATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG-3’) or 
XBP1 shRNA (Forward: 5’-
CCGGGACCCAGTCATGTTCTTCAAACTCGAGTTTGAAGAACATGACTGGGTCTTTTTG-3’, 
reverse: 5’- 
AATTCAAAAAGACCCAGTCATGTTCTTCAAACTCGAGTTTGAAGAACATGACTGGGTC-3’) 
were cloned in pLKO-Tet-On lentiviral vector. To produce lentiviruses, 293T cells were co-
transfected with the lentivirus expression vectors psPAX2 and pMD2.G using FuGene 6 
transfection reagent (cat. E2691, Promega). Lentiviruses were collected 48 hours after 
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transfection. For N-MycER SHEP cells, the infection efficiency was >95% after 2 days infection, 
examined by GFP positive cells. For Kelly cells, viruses were used with 8µg/mL polybrene for 
infection and cells were selected with 0.75µg/mL puromycin for 5 days to establish stable cell 
lines.  
RNA Interference 
        siRNA pools targeting human XBP1 (cat. L-009552), SCD (cat. L-005061), and non-
targeting pool control (cat. D-001810) were from Dharmacon. For P493 cells, 5*106 cells were 
electroporated using an Amaxa Nucleofector with Program O-06, Nucleofactor kit V (cat. VCA-
1003, Lonza) and 2µM siRNA for each reaction were used. For N-MycER SHEP cells, 
Lipofectamine RNAiMAX Reagent (cat. 13778, Invitrogen) was employed according to the 
manufacturer's instructions.  
Viability Assays 
        Cell viability was determined using the FITC-Annexin V, PI Kit (cat. 556547) or APC-Annexin 
V (cat. 550475) for GFP-positive cells from BD Biosciences according to the manufacturer's 
instructions. Flow cytometry was performed using the BD Accuri C6 instrument or BD 
FACSCalibur flow cytometer, and double-negative cells were determined viable.  
Cell Growth Assay 
        BL cell lines and CLL cells were seeded in 6-well plates and exposed to indicated treatments. 
Cells were counted at various time points using the Invitrogen Countess Automated Cell Counter 
(cat. C10281), as per the manufacturer's instructions. Control SHEP, 4-OHT SHEP, SK-N-AS, 
BE2C, and Kelly cells were seeded in 96-well plates and exposed to indicated treatments. At 
indicated time points, cell growth was analyzed using the WTS-1 reagent (cat. 11644807001, 
Roche), according to the manufacturer's instructions.  
Transmission Electron Microscopy 
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        P493 cells with or without c-Myc overexpression were cultured at a concentration of 5*105 
cells/mL. Cells were pelleted through centrifugation and washed with PBS once before fixation. 
Cells were then fixed with 2.5% glutaraldehyde, 2.0% paraformaldehyde in 0.1M sodium 
cacodylate buffer, pH 7.4, overnight at 4°C. After subsequent buffer washes, the sample were 
post-fixed in 2.0% osmium tetroxide for 1 hour at room temperature, and then washed again in 
buffer followed by distilled water. After dehydration through a graded ethanol series, the tissue 
was infiltrated and embedded in Embed812. Thin sections were stained with uranyl acetate and 
lead citrate and examined with a JEOL 1010 electron microscope fitted with a Hamamatsu digital 
camera and ATM Advantage image capture software. At least 30 cells were analyzed from each 
group, and representative images are shown. 
RNA Extraction, Real-time Quantitative RT-PCR, and RT-PCR Analysis 
        Total RNA was isolated using the RNeasy Mini Kit (cat. 74104, Qiagen), cDNA was 
synthesized using the High-Capacity RNA-to-cDNA Kit (cat. 4387406, ThermoFisher Scientific). 
qRT-PCR was performed on a ViiA7 Real-Time PCR system from Applied Biosystems. 
Predesigned Taqman primers were obtained from ThermoFisher Scientific for the following genes: 
TBP (HS00427620_M1), ACTB (HS01060665_G1), HSPA5 (HS00946084_G1), MYC 
(HS00153408_M1), MYCN (HS00232074_M1), XBP1t (HS00231936_M1), XBP1s 
(HS03929085_G1), LDHA (HS01378790_G1), ERN1 (HS00176385_M1), LXR 
(HS00172885_M1), FABP5 (HS02339437_G1), PPARA (HS00947536_M1), ACACA 
(HS01046047_M1), ACACB (Hs01565914_m1), FABP6 (HS01031183_M1), PPARD 
(HS04187066_G1), ACAT1 (HS00608002_M1), CPT1A (HS00912671_M1), CPT1B 
(HS03046298_S1), SCD (HS01682761_M1), ACLY (HS00982738_M1), FASN 
(HS01005622_M1), ACSS2 (HS01122829_M1), DGAT1 (HS01017541_M1), DGAT2 
(HS01045913_M1), PLIN2 (HS00605340_M1), PLIN3 (HS00998416_M1), HMGCS1 
(HS00940429_M1), HMGCR (HS00168352_M1), ODC1 (HS00159739_M1), HERPUD1 
(HS01124269_M1), DNAJB9 (HS01052402_M1), ATF3 (HS00231069_M1), and DDIT3 
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(HS00358796_G1). VeriQuest Fast Probe qPCR Master Mix (cat. 75680) was purchased from 
Affymetrix. SYBR-green primers were utilized for mouse Actb (forward: 5’-
AAATCTGGCACCACACCTTC-3’, reverse: 5’-GGGGTGTTGAAGGTCTCAAA-3’), mouse Xbp1t 
(forward: 5’-GGCTGTCTGGCCTTAGAAGA-3’, reverse: 5’-CTGTCAAATGACCCTCCCTG-3’), 
mouse Xbp1s (forward: 5’-GAGTCCGCAGCAGGTG-3’, reverse: 5’-GTGTCAGAGTCCATGGGA-
3’), human XBP1t (forward: 5’-GGCATCCTGGCTTGCCTCCA-3’, reverse: 5’-
GCCCCCTCAGCAGGTGTTCC-3’), human XBP1s (forward: 5’-CTGAGTCCGCAGCAGGTG-3’, 
reverse: 5’-TCCAAGTTGTCCAGAATGCC-3’). SYBR Green PCR Master Mix (cat. 4309155) was 
purchased from ThermoFisher Scientific. RT-PCR assay for XBP1 splicing was described 
previously (Oslowski and Urano, 2011). Primers for XBP1 are: forward: 5’-
CCTGGTTGCTGAAGAGGAGG-3’, reverse: 5’-CCATGGGGAGATGTTCTGGAG-3’. Primers for 
internal control 18S rRNA are: forward: 5’-GGCCCTGTAATTGGAATGAGTC-3’, reverse: 5’- 
CCAAGATCCAACTACGAGCTT-3’.  
Western Blot Analysis 
        Cells were lysed in 150mM NaCl, 10mM Tris PH7.6, 0.1% SDS, and 5mM EDTA containing 
Roche complete ultra protease/phosphatase inhibitor (cat. 05892791001). Nuclear fractionation 
was performed using NE-PER Nuclear and Cytoplasmic Extraction Reagents (cat. 78833, 
TheroFisher Scientific). Protein concentration was quantified with Pierce BCA Protein Assay Kit 
(cat. 23225, ThermoFisher Scientific). Isolated proteins were resolved by SDS-PAGE, and 
Western blot analysis was performed. IRE1α phosphorylation was monitored by Phos-tag SDS-
PAGE as described previously (Yang et al., 2010). All primary antibodies were diluted in 1:1,000 
in 5% w/v nonfat milk, unless otherwise noted. Blots were incubated with primary antibodies 
overnight at 4°C. XBP1s (cat. 619502, 1:500) antibody was from BioLegend. c-Myc (cat. 
ab32072), Actin (cat. ab3280), SCD1 (cat. ab19862) antibodies were purchased from Abcam. 
IRE1α (cat. 3294), BiP (cat.3177), PARP (cat. 9542), GAPDH (cat. 2118), total JNK (cat. 9252), 
phospho-threonine 183/185 JNK (cat. 9251), p62 (cat. 5114), LC3B (cat. 2775), N-Myc (cat. 
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9405), and HDAC1 (cat. 5356) antibodies were purchased from Cell Signaling Technology. 
DDRGK1 antibody (cat. HPA013373) was from Sigma Aldrich. HRD1 antibody (cat. NB100-2526) 
was from Novus. SEL1L antibody was generated in our laboratory. Primary antibodies were 
detected using horseradish peroxidase-conjugated secondary antibodies (Cell Signaling 
Technology) followed by exposure to enhanced chemiluminescence substrate (cat. 
NEL103001EA, PerkinElmer) or SuperSignal West Femto Maximum Sensitivity Substrate (cat. 
34095, ThermoFisher Scientific).  
Chromatin Immunoprecipitation (ChIP) and ChIP-qPCR Assay 
        This assay was performed as described previously (Chen et al., 2014). qPCR using SYBR 
Green was performed per manufacturer’s protocol. The primers used for positive control ERdj4 
are forward: 5’- GCAGCAACAACAGTTTTCCA-3’, reverse: 5’-GCACCCTAATCTCGGTCGTA-3’. 
Primers for negative control are forward: 5’-TTCAGGGGAAGAAAAACTTGGGA-3’, reverse: 5’-
TCCGAAAAACCCCTGCACTC-3’, which is located upstream of the SCD promoter. Primers for 
XBP1s binding site within the SCD promoter region are forward: 5’-
AGAGGGAACAGCAGATTGCG-3’, reverse: 5’-CTGTAAACTCCGGCTCGTCA-3’. 
Analysis of Lipids by Fatty Acid Methyl Esterification (FAME) 
        Gas chromatography/mass spectrometry (GC/MS) analysis was used to examine total 
cellular fatty acids either with or without 13C enrichment.  U-13C-glucose was used to allow 
differentiation between de novo and non de novo produced lipids.  For 13C enrichment studies, 
cells were cultured in RPMI 1640 media (cat. 11879020, ThermoFisher Scientific), and 
supplemented with 5% dialyzed FBS (cat. 100-108, Gemini Bio-products), with all unenriched 
glucose replaced with U-13C-glucose. Cells were cultured to a level of 5*105/mL in T-75 flasks.  
Subsequently, they were collected by centrifugation and washed three times with ice cold PBS. 
The second PBS wash contained 1% fatty-acid-free albumin to remove residual lipids from the 
medium. After the last centrifugation, 1 mL of cold methanol was added prior to storage at -80 C.  
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A standard Bligh-Dyer chloroform extraction was used to recover both polar and non-polar lipids 
(BLIGH and DYER, 1959).  Cells were initially sonicated in 2.7 ml of 75% methanol/25% water.  
Subsequently, chloroform and water were added to give a final mixture containing 38:31:31 
methanol/water/chloroform.  The mixture separated into two phases with the lipids in a 
chloroform-rich hydrophobic phase.  After centrifugation, the bottom hydrophobic phase (~1.3 ml) 
was removed with a glass pipette.  A second extraction with 0.7 ml chloroform was used to 
recover additional lipids from the methanol/water phase.   The two hydrophobic fractions were 
combined in a single glass centrifuge tube and back extracted with 0.15 ml of de-ionized water. 
The hydrophobic fraction was dried under nitrogen in 30-ml thick-wall glass anaerobic tubes. 
        The dried lipid extracts were dissolved in 2 ml of a 4:1 methanol/toluene mixture that 
contained butylated hydroxytoluene (0.45 mM).  Acetylchloride (14 mM) was added to produce 
catalytic H+ in situ for the methyl esterification reaction.  The anaerobic tubes containing the 
reaction mixtures were capped with thick butyl rubber stoppers (Bellco) and heated at 100 °C for 
1 hour. After cooling, the reaction mixtures were mixed with 0.56M aqueous sodium carbonate at 
a ratio of 2:5 to drive the fatty acid methyl esters into a hydrophobic phase that floated on top of 
the aqueous phase.  The toluene was purified by centrifugation and analyzed with an Agilent 
7890A GC/MS (7890A/5975C). Mass spectra were quantified with the MSD ChemStation 
software from Agilent. Isocor, written for the Python programming environment (www.python.org), 
was used to correct mass spectra for natural abundance contributions from 13C. Mean enrichment 
was calculated as: where: fi = fractional enrichment of the i-th carbon and n is the total number of 
carbons.   
 
 
Cell Staining and Imaging 
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        P493 cells were cytospun onto the slides through CytoSep Dual Sample Chamber (cat. 
M967-20FW, Medline Industries, Inc.) in a 7620 Cytopro Cytocentrifuge Centrifuge (Wescor) at 
212g for 7 minutes. For immunofluorescence, slides were incubated with 50mM ammonium 
chloride for 10 minutes, permeabilized with 0.25% Triton X-100 for 10 minutes, and blocked with 
2% BSA for 30 minutes. Slides were then incubated with Ki-67 primary antibody (cat. 550609, BD 
Pharmingen) at 1:100. Secondary Alex Fluor 594 goat anti-mouse antibody (cat. R37121, 
ThermoFisher Scientific) was used at 1:200 for 1 hour at room temperature. Slides were mounted 
in Prolong Gold Antifade with DAPI (cat. P36935, ThermoFisher Scientific) before imaging. 
TUNEL staining was performed using ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit 
(cat. S7111, Millipore), according to the manufacturer's instructions.          
Oleic acid, Palmitic acid, and Palmitoleic acid Treatment 
        Oleic acid-BSA conjugation solution was purchased from Sigma Aldrich, in which oleic acid 
was dissolved in 10% BSA, the concentration of oleic acid is 3.33mM. For palmitic acid and 
palmitoleic acid, the powder was dissolved in 50% ethanol at 65°C until completely dissolved to 
achieve a 50mM stock, and then conjugated with BSA in 10% BSA solution to concentration of 
3.33mM at 37°C for 1 hour. For the combination treatment, oleic acid and palmitic acid were 
added 1:1 to the medium. 
Xenograft Tumors 
        For P493 High Myc xenografts and B-I09 treatment, 1.5*107 P493 High Myc cells were 
injected subcutaneously into the flank of 6-week-old female homozygous athymic nude mice 
(Strain code 490, Charles River Laboratories). When the tumor volumes reached approximately 
150mm3, B-I09 was administered intraperitoneally at 50mg/kg on the first 5 days of each week for 
2 weeks. For Ramos xenografts and SCDi treatment, 1*106 Ramos cells were introduced 
subcutaneously into the flanks of 10-week-old female homozygous C.B-17 SCID mice (Strain 
code 236, Charles River Laboratories). When tumor volumes reached approximately 50-150mm3, 
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SCDi was orally administered at 5mg/kg (dissolved in 0.5% methy cellulose) twice daily. For Kelly 
xenografts, 3*106 Kelly cells with tet-inducible SCR or tet-inducible shXBP1 construct were 
injected subcutaneously into the left or right flank of 5-week-old homozygous female BALB/c 
Nude mice (Strain code 194, Charles River Laboratories), respectively.  When the tumor volumes 
reached approximately 50-150mm3, dox diet (cat. S3888, Bio-Serv) was administered to the mice. 
Tumor volume was monitored by caliper measurements.  
Mice, Tumor Formation, and B Cell Purification 
        Mice carrying the human MYC oncogene under the control of the Igλ regulatory elements 
(Kovalchuk et al., 2000) were crossed with wild-type C57BL/6J mice (Mouse strain 000664, The 
Jackson Laboratory), monitored for lymphoma development, and sacrificed when moribund (3-5 
months old). Total RNA from superficial cervical lymphomas and mesenteric lymphomas from the 
same mouse was extracted for further analysis. For wild-type B cell purification, naïve B 
lymphocytes were purified from C57BL/6J mice spleens by magnetic depletion of CD43-positive 
cells (Miltenyi Biotech), according to manufacturer's instructions. LAP/MYC mice were described 
previously (Xiang et al., 2015). mRNA was extracted from 5 liver tumors and paired normal liver 
tissues from this mouse model for qRT-PCR analysis.   
Statistics 
        For calculation of the Contribution Ratios to viability restoration corresponding to Figure 17E, 
Figure 18F, and Figure 19E. The Contribution Ratios of BSA were calculated using relative 
viability of B-I09+BSA to divide B-I09 treatment alone; while the Contribution Ratios of OA were 
calculated using relative viability of B-I09+OA to divide B-I09+BSA. For the correlation between 
HSPA5 expression and Myc signature (Figure 1D, and Table 1), raw data for 22 samples of 
interest in GSE2350 were downloaded from the GEO database. Multi-array average (RMA) was 
performed separately on the 9 and 13 samples, which were run on HG_U95A and HG_U95Av2, 
respectively. Resulting log2-transformed normalized intensities were quantile normalized across 
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all samples to lessen the platform-specific effects. Correlation of all genes across all samples was 
calculated against HSPA5 (probeset ID 36614_at). P-value and FDR-corrected P-value were 
calculated for each gene. The set of genes with corrected P-values of ≤0.01 (106 genes) was 
overlapped with the set of genes described to be Myc-related in the Hallmark sets from MSigDB 
(Myc Union, 240 genes). A Fisher's exact test was performed showing the overlap between these 
two lists and the full set of genes included in the array design. The overlap of 6 genes gave a P-
value of 0.0364. Where necessary, data were statistically analyzed to generate mean ± standard 
deviation (SD). The levels of significance were determined using two tailed Student's t test, two-
way ANOVA with Bonferroni correction, or two tailed paired t test. Where appropriate, P values 
are provided in the figures or in the legends. P<0.05 was considered statistically significant. 
Study Approval 
        All experiments involving the use of mice were performed following protocols approved by 
the Institutional Animal Care and Use Committee at the University of Pennsylvania. 
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CHAPTER 3 Results 
 
ER stress and the IRE1α-XBP1 pathway are enhanced in human and mouse BL 
        Previous reports suggested a relationship between c-Myc expression and ER stress, 
although the details of this interaction remain unclear (Hart et al., 2012). We employed BL as a c-
Myc-dependent disease model, in which MYC translocation into immunoglobulin loci leads to its 
constitutive transcriptional dysregulation and expression (Schmitz et al., 2014). Analysis of 
Oncomine data (www.oncomine.org) revealed that HSPA5 mRNA, which encodes the ER 
chaperone BiP, is elevated in BL cells relative to normal centroblasts (CB) (Figure 1B), a BL cell 
of origin. HSPA5 levels also correlated with MYC mRNA abundance and an established c-Myc 
signature (Figure 1C and 1D, and Table 1), suggesting that increased c-Myc engages ER stress 
response pathways in BL patients. We initially focused on the IRE1α arm of the UPR, whose 
regulatory and functional mechanisms have not been previously investigated in this setting. Gene 
expression profiles of two independent BL patient cohorts (Basso et al., 2005; Brune et al., 2008) 
revealed elevated XBP1s target mRNAs (So et al., 2012), relative to centroblasts (Figure 2A), 
consistent with increased IRE1α RNase activity and XBP1s accumulation. Interestingly, RIDD 
was not engaged, as indicated by the overexpression (rather than underexpression) of multiple 
RIDD targets in BL (Figure 2B). In addition, ratios of Xbp1s to total Xbp1 (Xbp1t) transcripts, an 
indicator of IRE1α RNase activity, were elevated in Eλ/MYC murine BL lymphoma cells 
(Kovalchuk et al., 2000) and LAP/MYC murine hepatocellular carcinoma cells (Xiang et al., 2015), 
compared to their normal counterparts (Figure 3A and 3B), demonstrating that elevated c-Myc 
induces IRE1α RNase activity in multiple cancer types. 
 
 
 
 
18	
	
A
CB BL
3
4
5
6
lo
g2
 m
ed
ia
n-
ce
nt
er
ed
 in
te
ns
ity
HSPA5
P=0.0004
B
C
0 2 4 6
3
4
5
6
H
SP
A5
Correlation
MYC
R2=0.4033
P=0.0015
D
IRE1α
XBP1u
XBP1s 
XBP1s 
BiP 
ER 
Nucleus 
BiP 
BiP BiP 
BiP 
BiP 
0
100
6
0
9297 217 17
HSPA5 Correlation (106)
Platform Symbols (9620) Myc Union (240)
Fisher’s exact test (P=0.0364)
 
 
 
Figure 1: ER stress is enhanced in human BL. 
A) Schematic model of the IRE1α-XBP1 pathway. 
B) log2 median-centered intensity of HSPA5 in human BL (n=17) and CB (n=5, two-tailed 
Student t test). Microarray data were obtained from the Oncomine database. Whiskers 
denote the minimal to maximal values. 
C) Correlation of MYC and HSPA5 in samples from (B). R2 and P value were determined by 
a two-tailed Pearson correlation test. 
D) Correlation between HSPA5 and an established Myc signature (see Methods for details). 
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 Myc Union Not Myc Union Total 
HSPA5 correlation 6 100 106 
HSPA5 no correlation 217 9297 9514 
Total 223 9397 9620 
 
Table 1. Fisher’s exact test to determine correlation between HSPA5 and Myc signature. 
Raw data for 22 samples of interest in GSE2350 were downloaded from the GEO database. RMA 
was performed separately on the 9 and 13 samples, which were run on HG_U95A and 
HG_U95Av2, respectively. Resulting log2-transformed normalized intensities were quantile 
normalized across all samples to lessen the platform-specific effects. Correlation of all genes 
across all samples was calculated against HSPA5 (probeset ID 36614_at). P-value and FDR-
corrected P-value were calculated for each gene. The set of genes with corrected P-values of 
≤0.01 (106 genes) was overlapped with the set of genes described to be Myc-related in the 
Hallmark sets from MSigDB (Myc Union, 240 genes). A Fisher's exact test was performed 
showing the overlap between these two lists and the full set of genes included in the array design. 
The overlap of 6 genes gave a P-value of 0.0364. 
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Figure 2. IRE1α-XBP1 signaling, but not RIDD is enhanced in human BL. 
A. In two independent cohorts of BL patients and CB controls, heatmap shows the relative 
expression of genes directly regulated by XBP1s. Data were extracted from the 
Oncomine database. Expression signals are depicted using pseudo-coloring, in which 
expression for each gene is shown as high (red) or low (blue). 
B. Comparison of RIDD targets between BL and CB. Data were obtained from the 
Oncomine database. P<0.05 was regarded as significant (two tailed Student t test). Grey 
circles show genes without significant changes, read squares denote genes those are 
significantly upregulated in BL patients, while blue rhombuses represent significantly 
downregulated genes in BL. 
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Figure 3. IRE1α-XBP1 signaling is enhanced in murine BL and hepatocellular carcinoma. 
A. qRT-PCR analysis of Xbp1s/Xbp1t ratios in mixed B lymphocytes isolated from 2 wild-
type (WT) mouse spleens and tumor cells from superficial and mesenteric lymphomas in 
7 Eλ/MYC mice. Actb was utilized as the endogenous control gene, and relative mRNA 
expression was determined by normalizing to expression in WT B lymphocytes. 3 
technical triplicates were used in each sample.  
B. mRNA was extracted from liver tumors and paired normal liver tissues from the LAP/MYC 
mouse model. MYC and Xbp1s/Xbp1t examined with qRT-PCR. Actb was used as an 
endogenous control gene. Relative mRNA expression was determined by normalizing to 
levels in each normal sample. Three technical triplicates were used in each sample. 
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c-Myc activation initiates ER stress and the IRE1α-XBP1 pathway through multiple 
mechanisms 
        To study the effect of c-Myc on ER stress responses, we employed human P493 B-cell 
lymphoma cells, in which c-Myc levels can be manipulated with tetracycline and beta-estradiol 
(Yustein et al., 2010) (annotated by "No Myc", "Low Myc", and "High Myc") (Figure 4A). Cell 
proliferation, cell size, total RNA content, and protein content increased proportionally with c-Myc 
abundance (Figure 4A-4C). Along with the canonical target gene LDHA, c-Myc induction 
correlated with elevated ERN1 (IRE1α), HSPA5 (BiP), XBP1t, XBP1s (XBP1s), and 
XBP1s/XBP1t (Figure 4D-4F), suggesting that c-Myc regulates multiple components of the IRE1α 
stress response pathway in these cells.  
        c-Myc appeared to induce the IRE1α-XBP1 pathway through a variety of mechanisms. First, 
re-stimulation of previously c-Myc-depleted P493 cells via tetracycline withdrawal revealed a 
time-dependent increase in LDHA, ERN1, HSPA5, XBP1t, and XBP1s mRNA (Figure 5A) and 
protein (Figure 5B), with maximal expression levels achieved by 24-48 hours. Importantly, IRE1α, 
BiP, XBP1s, and c-Myc protein levels in P493 High Myc cells were comparable to multiple bona 
fide BL cell lines: Raji, Daudi, Ramos, and EB-2 (Figure 5C), consistent with the notion that P493 
High Myc cells are a faithful BL model (Yustein et al., 2010). Chromatin immunoprecipitation-
sequencing (ChIP-seq) analysis of P493 cells confirmed c-Myc binding to E-box sequences in the 
ERN1, HSPA5, and XBP1 promoters, confirming that c-Myc activates their transcription directly 
(Figure 5D). Second, c-Myc regulates IRE1α RNase activity, as demonstrated by increased 
XBP1s/XBP1u ratios (Figure 4E) and phosphorylated IRE1α protein levels (Figure 4F) in c-Myc 
expressing cells.  Consistent with this observation, XBP1s/XBP1t ratios were reduced upon c-
Myc suppression, but only fully restored 48 hours post c-Myc induction (Figure 5A and 5B). These 
data likely reflect a delay between c-Myc-dependent target gene induction (<24 hours) and 
accumulation of sufficient misfolded/unfolded proteins to stimulate IRE1α RNase activity 
(between 24 hours and 48 hours). Third, utilizing a cycloheximide (CHX) chase assay, we 
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observed that IRE1α protein half-life was regulated by c-Myc (Figure 6A). IRE1α protein stability 
can be positively regulated by DDRGK domain-containing protein 1 (DDRGK1) through 
ufmylation modification (Liu et al., 2017). However, in contrast to a previous study, this may be 
DDRGK1 independent in BL, as DDRGK1 expression was negatively correlated with IRE1α 
stability in P493 cells (Figure 6B). In addition, Sun et al. demonstrated that IRE1α is a substrate 
of the SEL1L-HRD1 ERAD complex, and ERAD-mediated IRE1α degradation is attenuated by 
ER stress (Sun et al., 2015). However, no significant changes in SEL1L1 or HRD1 protein levels 
were observed in P493 cells with variable c-Myc expression (Figure 6C and 6D), suggesting that 
the exact mechanism of how c-Myc regulates IRE1α protein stability needs to be further 
investigated.  
        Treating c-Myc-overexpressing BL cell lines with the non-specific Myc inhibitor JQ1 (Figure 
7A and 7B) or low dose CHX (Figure 7C) significantly reduced HSPA5 and XBP1s transcripts and 
proteins, as well as XBP1s/XBP1t ratios. Consistent with these biochemical findings, transmission 
electron microscopy revealed an irregular ER structure, with substantially expanded membranes 
and distended lumens in c-Myc-overexpressing P493 cells (Figure 7D). Taken together, our data 
are consistent with a model in which c-Myc engages the IRE1α-XBP1 stress pathway through 
multiple mechanisms (Figure 7E), by: 1) directly activating ERN1, HSPA5, and XBP1 transcription, 
2) stabilizing IRE1α protein, and 3) increasing ER protein load, thereby activating IRE1α RNase 
activity and promoting XBP1 splicing (See Discussion).  
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Figure 4. c-Myc activation impacts ER stress and the IRE1α-XBP1 pathway. 
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A. Growth curve and immunoblot analysis for P493 cells with different levels of c-Myc 
expression (annotated as “No Myc”, “Low Myc”, and “High Myc”, n=3). 
B. Left: P493 No Myc, Low Myc, and High Myc cells analyzed by flow cytometry to 
determine cell size using forward scatter (results are representatives of >3 independent 
experiments). Right: quantification of relative cell size (n=3, two-way ANOVA test with 
Bonferroni correction). 
C. Total RNA (n=3) and protein (n=6) content of one million P493 No Myc, Low Myc, and 
High Myc cells determined by Nanodrop 1000 and BCA protein quantification, 
respectively (two-way ANOVA test with Bonferroni correction) 
D. qRT-PCR analysis of LDHA, ERN1, HSPA5, XBP1t, XBP1s, and XBP1s/XBP1t ratios in 
P493 cells with different levels of c-Myc (n=3, two-way ANOVA test with Bonferroni 
correction).  
E. RT-PCR analysis of XBP1 splicing in P493 cells, and quantification of band intensity of 
XBP1s/XBP1u, relative intensity was determined by normalizing to the ratio of No Myc 
cells. 
F. Immunoblot analysis for IRE1α phosphorylation (phos-tag SDS-PAGE), BiP, and XBP1s 
in P493 cells. SE, short time exposure; LE, long time exposure. For qRT-PCR, ACTB 
was utilized as the endogenous control gene. *, P<0.05, **, P<0.01, ***, P<0.001. 
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Figure 5. c-Myc transcriptionally regulates ERN1, HSPA5, and XBP1. 
A. In P493 cells, c-Myc was suppressed with tetracycline (0.1µg/mL) for 24 hours, which 
was then withdrawn to re-express c-Myc. At indicated times, mRNA was collected for 
qRT-PCR analysis. Three technical triplicates were used in each sample, and results are 
representative of >3 independent experiments. ACTB was utilized as the endogenous 
control gene. 
B. Corresponding RT-PCR analysis of XBP1 splicing and protein expressions of IRE1α, BiP, 
XBP1s, and c-Myc in the same experimental settings of (A). 
C. Immunoblots comparing protein levels between P493 cells and 4 bona fide BL cell lines: 
Raji, Daudi, Ramos, and EB-2. 
D. ChIP-seq analysis shows binding of c-Myc to the promoters of ERN1, HSPA5, and XBP1 
in P493 cells, canonical (CACGTG) or non-canonical (CACGCG) E-boxes were found in 
the binding regions.  
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Figure 6. c-Myc regulates IRE1α protein stability. 
A. Immunoblots of IRE1α decay in P493 cells with different c-Myc levels after treatment with 
100µg/mL cycloheximide for the indicted times. The graph represents the quantification 
of IRE1α protein levels. 
B. Immunoblots for DDRGK1 expression in P493 No Myc, Low Myc, and High Myc cells. 
C. Immunoblots for SEL1L and HRD1 expression in P493 No Myc, Low Myc, and High Myc 
cells. 
D. Protein expression of SEL1L and HRD1 in experiment of Figure 5B. 
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Figure 7. Inhibition of c-Myc and protein synthesis suppresses IRE1α-XBP1 pathway. 
A. qRT-PCR analysis of Raji cells treated with 500nM JQ1 for 24 hours. 
B. immunoblot analysis of BL cell lines (Raji, Ramos, and Daudi) treated with 500nM JQ1 
for 24 hours or 48 hours. 
C. qRT-PCR analysis of Ramos cells treated with 0.1µg/mL CHX for 4 hours. 
D. Comparison of ER structures using transmission electron microscopy in P493 cells with 
or without c-Myc overexpression. Scale bar, 500nm. 
E. Schematic model of c-Myc regulating ER stress and the IRE1α-XBP1 pathway: 1) c-Myc 
directly activates ERN1, HSPA5, and XBP1 transcription, 2) c-Myc stabilizes IRE1α 
protein with unknown reasons, and 3) c-Myc increases ER protein load, thereby 
activating IRE1α RNase activity and promoting XBP1 splicing. For qRT-PCR, ACTB was 
utilized as the endogenous control gene. Results are representative of 3 independent 
experiments. *, P<0.05, **, P<0.01, ***, P<0.001. 
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Synthetic lethality between c-Myc overexpression and IRE1α RNase activity inhibition in 
vitro and in vivo 
        To investigate the effects of IRE1α inhibition in the context of c-Myc overexpression, we 
used the highly specific IRE1α RNase inhibitor B-I09 (Figure 8A), which was previously shown to 
mimic XBP1 deficiency and suppress chronic lymphocytic leukemia (CLL) progression in vivo by 
inducing apoptosis without causing systemic toxicity (Tang et al., 2014). B-I09 treatment resulted 
in a dose-dependent decrease in XBP1s protein in P493 High Myc cells treated with tunicamycin 
(Figure 8B), which blocks N-linked glycosylation and amplifies ER stress (Oslowski and Urano, 
2011), without altering c-Myc levels (Figure 8B) or IRE1α phosphorylation (Figure 8C).  Similarly, 
B-I09 treated P493 High Myc cells displayed a dose-dependent decrease in cell proliferation and 
viability (Figure 8D and 8E). Importantly, the effects of B-I09 were subtler in Low Myc and No Myc 
cells, especially at ≤10µM, as shown by Ki-67 and TUNEL staining (Figure 8D and 8E, Figure 9A-
9C). It is noteworthy that the ability of B-I09 to specifically induce apoptosis in c-Myc-
overexpressing cells was significantly higher than that of Doxorubicin (Figure 10), a traditional 
chemotherapeutic drug targeting highly proliferating cells, or that of JQ1 (Figure 10), which 
showed potent anti-tumor effects in multiple types of cancers with either c-Myc or N-Myc 
overexpression (Delmore et al., 2011; Puissant et al., 2013). We also evaluated three CLL cell 
lines (MEC1, MEC2, and WaC3) with variable c-Myc levels (Figure 11A). Although at base line 
WaC3 cells grow much more slowly than MEC1 and MEC2 CLL cells (Figure 11A), they were 
more sensitive to B-I09 treatment induced growth arrest and apoptosis, as indicated by Annexin 
V/PI staining and PARP cleavage assay (Figure 11B). These results decrease the possibility that 
variable cell proliferation rates between P493 High Myc, Low Myc, and No Myc cells are a 
confounding factor for the effects of B-I09, and confirm that c-Myc overexpression could be an 
important indicator for B-I09 usage in different types of cancers. Similar effects were observed 
using 4µ8c, a distinct (albeit less potent) IRE1α RNase inhibitor (Cross et al., 2012; Tang et al., 
2014) (Figure 12A and 12B). Finally, B-I09 treatment inhibited P493 High Myc xenograft tumor 
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growth in vivo, with no obvious toxicity as indicated by the maintenance of mouse body weight 
during treatment (Figure 13A and 13B).  
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Figure 8. Synthetic lethality between c-Myc overexpression and IRE1α RNase inhibition 
with B-I09 in P493 cells. 
A. Chemical structure of B-I09. 
B. P493 High Myc cells treated with indicated concentrations of B-I09 for 24 hours; 5µg/mL 
tunicamycin was added 6 hours before harvesting. Immunoblots show the expression of 
IRE1α, XBP1s, and c-Myc.  
C. Western blot shows IRE1α phosphorylation (phos-tag SDS-PAGE) of P493 High Myc 
cells treated with indicated concentrations of B-I09, in the presence of DMSO or 5µg/mL 
tunicamycin for 6 hours. 
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D. Before experimental treatment, Low Myc cells were generated by culturing with 0.1µg/mL 
tetracycline and 1µM beta-estradio, while No Myc cells were generated by culturing with 
0.1µg/mL tetracycline alone. After 48 hours, cells were treated with different 
concentrations of B-I09, and counted at indicated time points (n=3, two-way ANOVA test 
with Bonferroni correction). *, P<0.05; ***, P<0.001. 
E. Representative contour plots of P493 High Myc, Low Myc, and No Myc cells treated with 
indicated concentrations of B-I09 for 48 hours and analyzed by Annexin V/PI staining. 
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Figure 9. 10µM B-I09 significantly induces cell proliferation arrest and apoptosis in P493 
High Myc cells, with much subtler effects in Low Myc and No Myc cells. 
A. Immunoblot analysis of XBP1s and c-Myc in P493 High Myc cells treated with 10µM B-
I09 for 48 hours.  
B. Ki-67 staining representative images (left) and quantifications (right) upon 10µM B-I09 
treatment for 48 hours.  
C. TUNEL staining representative images (left) and quantifications (right) upon 10µM B-I09 
treatment for 48 hours. For both Ki-67 and TUNEL staining, 5 fields per slide were 
quantified. Scale bar, 100µM. Two-way ANOVA with Bonferroni correction was used to 
determine significance. *, P<0.05, ***, P<0.001. n.s., not significant. 
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Figure 10. B-I09 has higher specificity to induce apoptosis in c-Myc overexpressing P493 
cells than Doxorubicin and JQ1. P493 cells treated with indicated concentrations of B-I09, 
Doxorubicin, or JQ1 for 48 hours. Viability was examined and relative viability determined by 
normalizing to cells treated with Control or DMSO. Results are representative of 3 independent 
experiments. *, "High Myc" vs. "Low Myc"; #, "High Myc" vs. "No Myc".  Two-way ANOVA with 
Bonferroni correction was used to determine significance. ***, P<0.001. ###, P<0.001. 
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Figure 11. The effects of B-I09 in CLL cell lines are not dependent on higher cell 
proliferation rate. 
A. Growth curve of CLL cell lines (MEC1, MEC2, and WaC3) (n=3); Immunoblots show 
expression of c-Myc and XBP1s of each.  
B. CLL cells treated with 20µM B-I09 for 72 hours, relative cell growth (n=3) and viability 
were determined. Immunoblots show expression of PARP cleavage upon B-I09 treatment. 
Two-way ANOVA with Bonferroni correction was used to determine significance. ***, 
P<0.001.  
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Figure 12. 4µ8c exhibits similar effects as B-I09 in P493 cells, albeit less potent. 
A. Cells cultured with different concentrations of 4µ8c, and counted at indicated times (n=3).  
B. Cells treated with indicated concentrations of 4µ8c for 48 hours. Viability was examined 
and relative viability determined by normalizing to viability of cells treated with DMSO. 
Results are representative of 3 independent experiments. *, "High Myc" vs. "Low Myc"; #, 
"High Myc" vs. "No Myc".  Two-way ANOVA with Bonferroni correction was used to 
determine significance. **, P<0.01; ***, P<0.001. ###, P<0.001. 
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Figure 13. Synthetic lethality between c-Myc overexpression and IRE1α RNase inhibition 
with B-I09 in vivo. 
A. Growth of P493 High Myc subcutaneous tumors treated with vehicle or B-I09 (50mg/kg 
intraperitoneally, once per day, 5 days per week, 2 weeks). Relative tumor volume was 
determined by normalizing to volume when treatment was started (n=6 for Control, n=5 
for B-I09, two tailed Student t test). *, P<0.05, **, P<0.01. 
B. Body weight of mice bearing P493 High Myc xenografts treated with Control or B-I09. 
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B-I09 suppresses growth and induces apoptosis in human and mouse BL cells 
        c-Myc is overexpressed in all BL cells tested (Figure 5C), which also exhibited growth and 
survival defects upon B-I09 exposure, although their sensitivity to the drug varied (Figure 14A-
14G). For example, B-I09 treated Ramos cells displayed a dose-dependent inhibition of XBP1 
splicing, reduced proliferation and viability, without apparent alterations in c-Myc protein levels or 
IRE1α phosphorylation (Figure 14A-14C). The modest increase in IRE1α protein abundance 
(Figure 14A) was consistent with previous studies of XBP1 deletion in leukemic and hepatic cells, 
and may reflect a negative feedback mechanism (Lee et al., 2008; Tang et al., 2014), or changes 
in IRE1α protein stability. Importantly, the viability of B-I09-treated Ramos cells was rescued by 
treatment with CHX (Figure 14D), indicating that elevated protein synthesis and proteotoxicity at 
least partially contribute to IRE1α activation. We employed Ramos (Epstein-Barr viral negative 
(EBV-)) and Daudi (EBV positive (EBV+)) cells as representatives of two categories of human BL 
(EBV- and EBV+) (FRCPH et al., 2012) for further study (see below). Finally, elevated IRE1α and 
XBP1s expression, and increased sensitivity to B-I09, was observed in 8498 cells isolated from 
the Eκ/MYC mouse lymphoma model, as compared to wild type murine B-lymphocytes (Figure 
14H). Collectively, these data suggest an essential protective role for IRE1α RNase activity 
downstream of elevated c-Myc in BL cells.  
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Figure 14. B-I09 suppresses growth and induces apoptosis in human and mouse BL cells. 
A. (Left) Ramos cells were treated with indicated concentrations of B-I09 for 24 hours. 
Western blot shows the expressions of IRE1α, XBP1s, and c-Myc. (Right) Immunoblots 
show IRE1α phosphorylation (phos-tag SDS-PAGE) of Ramos cells treated with indicated 
concentrations of B-I09, in the presence of DMSO or 5µg/mL tunicamycin for 6 hours. 
B. Ramos cells were treated with indicated concentrations of B-I09 for 72 hours, cell 
numbers were counted at indicated times (n=3). 
C. Ramos cells were treated with indicated concentrations of B-I09 for 48 hours, cell viability 
was examined and relative cell viability was determined by normalizing to viability upon 
DMSO treatment. Immunoblots show PARP cleavage with 10µM B-I09 treatment for 48 
hours. 
D. Ramos cells pre-treated with CHX (0.5µg/mL) for 2 hours, and then cultured with DMSO, 
5µM, or 10µM B-I09 for 48 hours. Cell viability was then examined and relative cell 
viability determined by normalizing to viability upon DMSO treatment, or DMSO+CHX 
treatment, respectively. 
E. Raji cells were treated with B-I09 for the indicated times, cell number was counted (n=3) 
and cell viability examined. 
F. Daudi cells were treated with B-I09 for the indicated times, cell number was counted (n=3) 
and cell viability examined. 
G. EB-2 cells were treated with B-I09 for the indicated times, cell number was counted (n=3) 
and cell viability examined. 
H. For B cells isolated from WT mouse spleens and 8498 cells from Eκ/MYC lymphoma 
tumor, protein expression of IRE1α, XBP1s, and c-Myc was compared, and their 
sensitivities to different B-I09 concentrations at 48 hours examined. For all viability 
assays, results are representative of 3 independent experiments; P values were 
determined by two-way ANOVA with Bonferroni correction. **, P<0.01; ***, P<0.001. n.s., 
not significant. 
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IRE1α RNase inhibition induces growth and viability defects by decreasing SCD1 
accumulation 
         There are multiple mechanisms whereby IRE1α might regulate growth and survival in c-
Myc-overexpressing cells. For example, the IRE1α cytoplasmic region also contains a kinase 
domain that phosphorylates and activates the c-Jun N-terminal kinase (JNK) pathway, inducing 
apoptosis (Urano et al., 2000). However, phospho-JNK protein levels were unaffected by B-I09 
treatment (Figure 15A).  Additionally, XBP1s can regulate the expression of BECN1, thereby 
inducing autophagy (Margariti et al., 2013; Tian et al., 2015), which confers a cytoprotective 
advantage in c-Myc-overexpressing mammalian (Hart et al., 2012) and Drosophila (Nagy et al., 
2013) cells. However, autophagy (based on p62 and LC3-II abundance) was not suppressed by 
B-I09 treatment (Figure 15B), indicating no decline in autophagic flux in this setting. 
        Both c-Myc and the IRE1α-XBP1 pathway have been previously implicated in regulating lipid 
metabolism in normal and malignant tissues (Cubillos-Ruiz et al., 2015; Lee et al., 2008; 
McGehee et al., 2009; Piperi et al., 2016; So et al., 2012), suggesting that alterations in lipid 
homeostasis trigger growth and viability defects in IRE1α inhibited, c-Myc-overexpressing BL 
cells. To investigate this possibility, we quantified mRNA levels of 20 lipid metabolism genes in 
IRE1α inhibitor treated P493 cells, including those involved in synthesis, storage, and catabolism 
(Figure 15C). B-I09 treatment inhibited XBP1 splicing, without altering c-Myc activity (based on 
unchanged LDHA levels). Expression of lipid synthesis genes, e.g. HMGCR1, HMGCS1, ACLY, 
ACACA, FASN, and SCD was increased by c-Myc and inhibited by B-I09 (Figure 15C). De novo 
lipogenesis generates diverse free fatty acids from glucose and glutamine, which can be probed 
by supplying uniformly 13C-labeled glucose (U-13C-glucose) and subsequent mass spectrometry 
analysis of saponified fatty acids (Kamphorst et al., 2011) (Figure 15D). Analysis at steady state 
labeling quantifies the unlabeled fraction (M+0) relative to labeled forms arising from lipogenesis. 
Consistent with mRNA expression, de novo lipogenesis was significantly higher in High Myc cells 
and suppressed by B-I09 treatment (Figure 15E).  
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Figure 15. B-I09 treatment affects lipid metabolism in P493 cells. 
A. P493 High Myc cells treated with 10µM B-I09 for 24 hours and 48 hours. Phospho-JNK 
and total JNK protein levels analyzed. 
B. P493 High Myc, Low Myc, and No Myc cells treated with 10µM B-I09 for 48 hours. 
Autophagy markers including p62 and LC3 analyzed by Immunoblots. 
C. Heatmap shows relative expression of lipid metabolism genes in P493 cells with different 
c-Myc levels upon 10µM B-I09 treatment for 48 hours (n=3). Expression signals are 
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depicted using pseudo-coloring, in which expression for each gene is shown as high (red) 
or low (blue). 
D. Schematic model of U-13C-glucose tracing and fatty acid labeling. 
E. U-13C-glucose tracing and fatty acid labeling in P493 High Myc and No Myc cells with 
10µM B-I09 treatment for 24 hours (n=3). Labeled/Total ratios were calculated for 
palmitate (C16:0), stearate (C:18:0), and Oleate (C18:1). 
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        We focused on SCD for several reasons: 1) SCD mRNA abundance was the most altered 
across different conditions among all genes tested (Figure 15C); 2) SCD encodes the rate-limiting 
enzyme in monounsaturated fatty acid formation. Furthermore, increased levels of 
monounsaturated fatty acids (e.g. C18:1 oleic acid) are a hallmark of human c-Myc driven 
lymphomas, based on comprehensive lipid profiling (Eberlin et al., 2014); and 3) previous work 
demonstrated that synthesizing or scavenging unsaturated lipids is critical to maintain cell viability 
in multiple transformed cell types, especially encountering elevated protein synthesis (Kamphorst 
et al., 2013; Young et al., 2013). Consistent with mRNA expression, decreased SCD1 protein 
accumulation upon IRE1α RNase inhibition was confirmed in multiple cell lines (Figure 16A-16C). 
More importantly, U-13C-glucose labeling enables us to determine SCD1 activity by calculating 
mean enrichment of labeled C18:1/C18:0 (Figure 15D), and we found that SCD1 enzymatic 
activity was dramatically inhibited by B-I09 effects on SCD1 abundance (Figure 16D).  
        ChIP analysis demonstrated XBP1s binding to the SCD proximal promoter, regulated by 
both tunicamycin (utilized to increase XBP1s expression) and B-I09 (Figure 16E), consistent with 
previous observations in mouse liver cells (Lee et al., 2008). XBP1 knockdown resulted in 
decreased levels of SCD1 protein (Figure 16F). SCD is a known c-Myc transcriptional target 
(Zeller et al., 2003) (Figure 15C); however, c-Myc protein levels were only modestly changed, if at 
all, in response to IRE1α RNase inhibition (Figure 16A-16C), suggesting that decreased SCD1 
was at least partly c-Myc-independent and XBP1s-dependent. In summary, we identified SCD as 
a transcriptional target downstream of IRE1α-XBP1 signaling in BL.  
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Figure 16. B-I09 treatment decreases SCD1 expression, and SCD (encoding SCD1) is 
transcriptionally regulated by XBP1s. 
A. Immunoblot analysis for P493 High Myc, Low Myc, and No Myc cells treated with DMSO 
or 10µM B-I09 for 48 hours. XBP1s, c-Myc, and SCD1 expression examined. 
B. Immunoblot analysis for P493 High Myc, Low Myc, and No Myc cells treated with DMSO 
or 20µM 4µ8c for 48 hours. XBP1s, c-Myc, and SCD1 expression examined. 
C. CLL cell lines treated with 20µM B-I09 for 48 hours; c-Myc and SCD1 expression 
monitored. 
D. Mean enrichment of C18:1/C18:0 was calculated in P493 High Myc cells from (Figure 
15E) (n=3, two tailed Student t test). 
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E. ChIP-qPCR assay performed using anti-XBP1s antibody to detect enriched gene 
promoter fragments in 3 conditions: Control (Ct); Tunicamycin (5µg/mL) treatment for 6 
hours (Tm); and Tunicamycin+B-I09 (10µM) treatment for 6 hours (Tm+B-I09). IgG was 
used as mock ChIP control. ERdj4 serves as a positive control for XBP1s binding. Values 
represent relative increase of real-time PCR signals compared to the signal of IgG ChIP 
under Control condition. 3 technical triplicates are presented. 
F. P493 High Myc cells transfected with non-targeting (NT) siRNA or siRNA targeting XBP1 
(siXBP1) for 48 hours, XBP1s and SCD1 expression levels were examined. 
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        To test the critical role of SCD1 in IRE1α-inhibited, c-Myc-overexpressing conditions, P493 
High Myc cells were cultured with the monounsaturated fatty acids oleic acid (OA, C18:1) or 
palmitoleic acid (POA, C16:1), which are the enzymatic products of SCD1. OA partly rescued cell 
proliferation (Figure 17A) and both OA and POA essentially restored cell viability without affecting 
the ability of B-I09 to reduce XBP1s and SCD1 expression (Figure 17B and 17C). However, a 
combination of OA and saturated palmitic acid (Palm, C16:0) did not rescue viability as effectively 
as OA alone, even though exposure to Palm itself was not toxic (Figure 17D). These results 
suggest that unsaturated fatty acids are critical to maintain the viability of B-I09-treated cells.  
         Because long-chain fatty acids are relatively insoluble in aqueous solutions, they were 
conjugated to lipid free-bovine serum albumin (BSA) before use. Surprisingly, control BSA 
partially rescued cell growth and viability in the absence of exogenous OA (Figure 17A, 17B, and 
17D). This raised the possibility that BSA might enter B-I09 treated cells through 
macropinocytosis (Commisso et al., 2013; Palm et al., 2015), and contribute to viability by 
supplying free amino acids, although free BSA could rescue viability by scavenging lipids in the 
medium (Francis, 2010). To test this, cells were cultured in medium with reduced lipid 
concentration (see Methods). Treatment with B-I09 significantly reduced cell viability in lipid-
limited conditions, and whereas exogenous BSA alone rescued the viability of multiple B-I09 
treated cell lines in replete medium, it had no significant effect on the survival of lipid-limited cells. 
In contrast, addition of exogenous BSA-conjugated OA fully rescued viability in lipid-limited cells, 
suggesting that BSA functioned primarily as a fatty acid shuttle in these experiments (Figure 17E). 
        A requirement for SCD1 function in c-Myc-overexpressing P493 cells was further validated 
using a commercially available SCD1 inhibitor (SCDi), which phenocopied B-I09 treatment by 
inducing growth arrest and cell death (Figure 17F and 17G). However, apoptosis was only 
induced after 72 hours treatment (Figure 17G), suggesting other mechanisms might also exist.  
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Figure 17. B-I09 treatment results in phenotypes dependent on SCD1 loss in P493 cells. 
A. Cell growth of P493 High Myc cells treated with 10µM B-I09, and rescued with BSA 
control or OA (n=3). 
B. Relative viability of P493 High Myc cells treated with 10µM B-I09, and rescued with BSA 
control, OA, or POA for 48 hours. 
C. Immunoblots of experiment from Figure 17A. 
D. P493 High Myc cells treated with DMSO or 20µM B-I09 for 48 hours, with OA, or Palm, or 
the combination (1:1 ratio), cell viability examined, and relative viability calculated by 
normalizing to DMSO treatment group. 
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E. P493 High Myc cells cultured in media with normal lipid concentration (100%) or 
delipidated condition (10%), treated with 10µM B-I09, and rescued with BSA or OA for 48 
hours. Contribution ratios of viability restoration of BSA and OA in 100% or 10% lipid 
media were calculated (see Methods for details). 
F. P493 cells treated with 0.5µM SCDi for 72 hours, cell growth were determined (n=3). 
G. P493 cells treated with 0.5µM SCDi for 72 hours, viability were examined. For viability 
assays, results are representative of 3 independent experiments. P values were 
determined by two-way ANOVA with Bonferroni correction, if not specified elsewhere. ***, 
P<0.001. 
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        The regulation of SCD1 by IRE1α-XBP1 signaling and its role in maintaining cell growth and 
survival were further validated in bona fide BL cell lines (Figure 18A-18G and Figure 19A-19F).  
Importantly, SCD expression was increased in BL cells relative to centroblasts (Figure 20A). 
Therefore, we evaluated the therapeutic potential of SCDi for BL growth in vivo. SCDi 
administration significantly decreased tumor growth and tumor weight (Figure 20B). However, this 
was also accompanied by a slight weight loss during treatment (Figure 20C), as observed in a 
previous study (Mason et al., 2012). Taken together, IRE1α RNase inhibition resulted in BL cell 
phenotypes, dependent on SCD1 loss. In addition, targeting SCD1 phenocopied B-I09 to 
decrease in vivo tumor growth.  However, based on the toxicity of SCDi, IRE1α RNase inhibition 
may be a safer therapeutic strategy for BL patients. 
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Figure 18. B-I09 treatment results in phenotypes dependent on SCD1 loss in Ramos cells. 
A. Immunoblot analysis of Ramos cells treated with indicated concentrations of B-I09 for 48 
hours. 
B. Cell growth of Ramos cells treated with 20µM B-I09, and rescued with BSA control or OA 
(n=3). 
C. Relative viability of Ramos cells treated with 10µM B-I09, and rescued with BSA control, 
OA, or POA for 48 hours. 
D. Immunoblots of experiment from Figure 18B. 
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E. Ramos cells treated with DMSO or 20µM B-I09 for 48 hours, with OA, or Palm, or the 
combination (1:1 ratio), cell viability examined, and relative viability calculated by 
normalizing to DMSO treatment group. 
F. Ramos cells cultured in media with normal lipid concentration (100%) or delipidated 
condition (25%), treated with 10µM B-I09, and rescued with BSA or OA for 48 hours. 
Contribution ratios of viability restoration of BSA and OA in 100% or 25% lipid media 
were calculated (see Methods for details). 
G. Relative viability of Ramos cells treated with 0.5µM SCDi, and rescued with BSA control 
or OA for 48 hours. For viability assays, results are representative of 3 independent 
experiments. P values were determined by two-way ANOVA with Bonferroni correction, if 
not specified elsewhere. **, P<0.01; ***, P<0.001; n.s., not significant. 
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Figure 19. B-I09 treatment results in phenotypes dependent on SCD1 loss in Daudi cells. 
A. Immunoblot analysis of Daudi cells treated with 10µM B-I09 for 48 hours. 
B. Cell growth of Daudi cells treated with 10µM B-I09, and rescued with BSA control or OA 
(n=3). 
C. Relative viability of Daudi cells treated with 10µM B-I09, and rescued with BSA control, 
OA, or POA for 48 hours. 
D. Immunoblots of experiment from Figure 19B. 
E. Daudi cells treated with DMSO or 10µM B-I09 for 48 hours, with OA, or Palm, or the 
combination (1:1 ratio), cell viability examined, and relative viability calculated by 
normalizing to DMSO treatment group. 
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F. Daudi cells cultured in media with normal lipid concentration (100%) or delipidated 
condition (25%), treated with 10µM B-I09, and rescued with BSA or OA for 48 hours. 
Contribution ratios of viability restoration of BSA and OA in 100% or 25% lipid media 
were calculated (see Methods for details). 
G. Relative viability of Daudi cells treated with 0.5µM SCDi, and rescued with BSA control or 
OA for 48 hours. For viability assays, results are representative of 3 independent 
experiments. P values were determined by two-way ANOVA with Bonferroni correction, if 
not specified elsewhere. **, P<0.01; ***, P<0.001; n.s., not significant. 
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Figure 20. SCDi treatment decreases Ramos xenograft growth in vivo. 
A. Normalized reads of SCD in human BL and CB from healthy donors. Microarray data 
were obtained from the Oncomine database. Whiskers denote the minimal to maximal 
values. P values were determined by two-tailed Student t test. 
B. Tumor growth and weight of xenografted Ramos tumors treated with Control or SCDi 
(5mg/kg, orally twice daily). P values were determined by two-tailed Student t test. **, 
P<0.01, ***, P<0.001. 
C. Body weight of mice bearing Ramos xenografts treated with Control or SCDi. 
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N-Myc overexpressing cells also engage the IRE1α-XBP1-SCD1 pathway to maintain 
viability 
        To determine if these findings extend to other Myc family members, we employed the “N-
MycER” SHEP neuroblastoma cell line in which N-Myc activity is induced by tamoxifen treatment 
(Figure 21A). N-Myc activation via 4-hydroxytamoxifen (4-OHT) increased XBP1 splicing (Figure 
21B and 21C) and XBP1s protein abundance (Figure 21D), indicating N-Myc also engages the 
IRE1α-XBP1 pathway. Whereas B-I09 had only modest effects on the proliferation of untreated 
“Control SHEP” cells (N-Myc negative), it robustly inhibited proliferation and induced apoptosis in 
4-OHT treated “N-Myc SHEP” cells (N-Myc positive), in both a dose- and time-dependent manner 
(Figure 22A-22D).  Furthermore, this decrease in cell viability was largely restored by CHX 
treatment (Figure 22E). Mechanistically, B-I09 treatment resulted in decreased SCD1 (Figure 
22F), and all phenotypes were partly or totally reversed by OA (Figure 22G and 22H). Similarly, 
N-Myc SHEP cells were more sensitive to SCDi treatment or SCD knockdown with siRNA than 
controls (Figure 22I and 22J). To confirm B-I09 IRE1α target specificity, cells were treated with 
scrambled shRNA (shSCR) or shRNA targeting XBP1 (shXBP1) (Figure 23A).  Like B-I09 
treatment, XBP1 depletion with shXBP1 decreased SCD1 protein levels and induced apoptosis in 
N-Myc SHEP cells, while Control SHEP were largely resistant (Figure 23A and 23B).  
        MYCN amplification is found in ~25% of neuroblastoma (NB) cases, and remains the best-
characterized genetic marker of high risk disease (Huang and Weiss, 2013). We compared three 
NB cell lines with or without MYCN amplification: SK-N-AS (no MYCN amplification), BE2C 
(MYCN amplification), and Kelly (MYCN amplification): cells with MYCN amplification expressed 
higher levels of HSPA5 and XBP1s, and exhibited enhanced sensitivity to B-I09 (Figure 24A and 
24B). Importantly, XBP1 knockdown in Kelly cells dramatically impaired tumor growth and tumor 
weight in vivo (Figure 24C-24E), without affecting overall mouse body weight (Figure 24F). In 
summary, like c-Myc, N-Myc overexpressing cells also engage the IRE1α-XBP1-SCD1 pathway 
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to maintain cell proliferation and viability, and targeting this axis could be a potential therapeutic 
strategy for N-Myc overexpressing cancers, e.g. NB.  
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Figure 21. N-Myc overexpression also engages the IRE1α-XBP1 pathway. 
A. (Upper) SHEP N-MycER cells were treated with 4-OHT (200nM) for indicated times to 
activate N-Myc nuclear translocation. N-MycER expression was examined in the nuclear 
fragment. (Lower) N-Myc target ODC1 examined with qRT-PCR upon N-Myc activation 
(n=3). 
B. XBP1s/XBP1t ratios examined with qRT-PCR upon N-Myc activation (n=3). 
C. XBP1 splicing analyzed by RT-PCR upon N-Myc activation, and relative band intensity 
was determined by normalizing to Control cells at 24-hour time point. 
D. XBP1s protein accumulation determined by Immunoblots upon N-Myc activation. 
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Figure 22. IRE1α-XBP1-SCD1 pathway is critical to maintain cell proliferation and viability 
in N-Myc overexpressing cells. 
A. SHEP cells cultured in vehicle (Control) or 4-OHT containing media for 48 hours before 
treatment with DMSO or B-I09. WST-1 assay was used to examine cell growth. Relative 
absorbance was determined by normalizing to absorbance at time 0 hour (n=6). 
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B. Control and 4-OHT SHEP cells were exposed to 100, 50, 25, 12.5, 6.25, 3.125, 
1.5625µM B-I09 for 72 hours, IC50 was then determined (n=3, P value was determined by 
two-tailed Student t test). 
C. Representative contour plots of Control and 4-OHT SHEP cells treated with 30µM B-I09 
for 96 hours. 
D. Control and 4-OHT SHEP cells treated with indicated concentrations of B-I09 for different 
times, viability was then measured. Relative viability was determined by normalizing to 
viability of cells with DMSO treatment.  
E. SHEP cells pre-treated with CHX (0.5µg/mL) for 2 hours, and then cultured with DMSO or 
30µM B-I09 for 72 hours. Relative viability was determined by normalizing to viability 
upon DMSO treatment, or DMSO+CHX treatment, respectively. 
F. Immunoblots analysis for Control and 4-OHT SHEP cells with B-I09 treatment for 72 
hours. 
G. Control or N-Myc SHEP cells treated with DMSO or 30µM B-I09, rescued with BSA or OA 
for 72 hours (n=6). Absorbance was measured using WST-1 reagents. *, comparison of 
B-I09 and DMSO treatment. #, comparison of B-I09+BSA or B-I09+OA and B-I09 
treatment. 
H. Control or N-Myc SHEP cells treated with DMSO or B-I09, and rescued with BSA or OA 
for 72 hours. Viability was examined and relative viability was determined by normalizing 
to viability upon DMSO treatment. *, comparison of B-I09 and DMSO treatment. #, 
comparison of B-I09+BSA or B-I09+OA and B-I09 treatment.   
I. Control or N-Myc SHEP cells treated with 0.5µM SCDi for indicated times, viability was 
examined. Relative viability was determined by normalizing to viability of cells with DMSO 
treatment. 
J. Control or N-Myc SHEP cells treated with siNT or siSCD for 72 hours, and viability was 
determined. Relative viability was determined by normalizing to viability of cells with siNT 
treatment. For viability assays, results are representative of 3 independent experiments. 
P values were determined by two-way ANOVA with Bonferroni correction, if not specified 
elsewhere. *, P<0.05, ***, P<0.001. ###, P<0.001. n.s., not significant. 
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Figure 23. XBP1 depletion results in apoptosis in N-Myc overexpressing SHEP cells. 
A. SHEP cells infected with lentivirus containing shSCR or shXBP1 constructs for 48 hours, 
and vehicle or 4-OHT subsequently added. After 72 hours, cells were for Immunoblots 
analysis of XBP1s and SCD1. 
B. SHEP cells infected with lentivirus containing shSCR or shXBP1 constructs for 48 hours, 
and vehicle or 4-OHT subsequently added. After 72 hours, cells were imaged and 
harvested for viability assays. For viability assays, results are representative of 3 
independent experiments. P values were determined by two-way ANOVA with Bonferroni 
correction. ***, P<0.001. n.s., not significant. 
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Figure 24. XBP1 depletion sensitizes N-Myc overexpressing neuroblastoma cells to growth 
inhibition in vitro and in vivo. 
A. qRT-PCR comparing 3 neuroblastoma cell lines SK-N-AS, BE2C, and Kelly in terms of 
expressions of MYCN, ODC1, HSPA5, and XBP1s. 
B. Three neuroblastoma cell lines were tested for IC50 of B-I09 treatment for 72 hours. 
C. Kelly cells with tetracycline inducible shSCR or shXBP1 constructs injected 
subcutaneously into the left or right flanks of mice, respectively. When tumor sizes 
reached 50-150mm3, doxycycline chow was used to knockdown XBP1. Tumor volume 
was monitored every 3 days; tumor weight was measured upon harvesting (two tailed 
paired t test). 
D. Bulk tumors are shown: 2 tumors from the same mouse are shown together; left, Tet-
shSCR; right, Tet-shXBP1. 
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E. Validation of XBP1 knockdown in Kelly xenograft tumors by qRT-PCR (two-tailed paired 
Student t test). 
F. Body weight of mice bearing Kelly xenograft tumors (n=10). For qRT-PCR, TBP and 
ACTB were used as endogenous control genes, 3 technical triplicates were used in each 
sample, and data are representative of 3 independent experiments. *, P<0.05, **, P<0.01, 
***, P<0.001. n.s., not significant. 
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B-I09 enhanced in vitro cytotoxicity of BL chemotherapeutic drugs  
        Given the c-Myc-dependent toxicity of B-I09 observed in BL cell lines, we explored whether 
B-I09 treatment would improve standard therapies currently used to treat BL clinically. Apoptosis 
triggered in BL cells by either doxorubicin or vincristine treatment was further enhanced by B-I09. 
Combination indices (CIs) showed additive or synergistic effects with doxorubicin and vincristine 
in Daudi and Ramos cells (Figure 25A-25C, Table 2), and the effects of B-I09 depend on SCD1 
activity, as SCD1 downregulation was maintained with combinational treatment and OA partially 
rescued cell viability (Figure 25D and 25E). These results suggest that B-I09 and other IRE1α 
inhibitors could be used to treat a variety of Myc-driven malignancies, including c-Myc 
overexpressing BL and N-Myc overexpressing neuroblastoma, to improve standard of care. 
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Figure 25. B-I09 combination indices (CI) with Doxorubicin and Vincristine. 
A. Daudi cells treated with Doxorubicin plus B-I09 for 48 hours. 
B. Ramos cells treated with Vincristine plus B-I09 for 48 hours. 
C. Daudi cells treated with Vincristine plus B-I09 for 48 hours. Relative viability was 
determined by normalizing to viability upon DMSO treatment. 
D. Western blot examining SCD1 expression after treatment with 10µM B-I09 or 0.5µM 
Vincristine alone, or the combination of both in Daudi and Ramos cells after 48 hours. 
E. Daudi or Ramos cells treated with 10µM B-I09 or 0.5µM Vincristine alone, or the 
combination of both, rescued with OA for 48 hours, viability was determined. Data are 
representative of 3 independent experiments. 
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B-I09 combination Indices (CI) with Doxorubicin in Daudi 
Doxorubicin (nM) B-I09 (µM) CI value 
6.25 5 0.842 
12.5 5 0.798 
25.0 5 0.758 
6.25 10 0.866 
12.5 10 0.853 
25.0 10 0.835 
   
B-I09 combination Indices (CI) with Vincristine in Daudi 
Vincristine (nM) B-I09 (µM) CI value 
0.5 5 0.796 
1 5 0.625 
5 5 0.700 
0.5 10 0.659 
1 10 0.581 
5 10 0.520 
   
B-I09 combination Indices (CI) with Vincristine in Ramos 
Vincristine (nM) B-I09 (µM) CI value 
0.3 10 0.995 
0.5 10 0.785 
0.7 10 0.618 
0.3 20 0.797 
0.5 20 0.547 
0.7 20 0.437 
 
Table 2. B-I09 combination indices (CI) with Doxorubicin and Vincristine in Daudi and 
Ramos cells. CI was calculated using CompuSyn software. CI<0.9 indicates synergistic effects, 
0.9<CI<1.1 indicates additive effects, and CI>1.1 indicates antagonistic effects. 
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Discussion 
        Myc overexpression drives tumor growth and progression by altering the expression of 
thousands of target genes that regulate myriad cellular processes (Dang, 2012). Although Myc-
transformed tumors are highly dependent on sustained Myc transcriptional activity, directly 
inhibiting Myc as a therapeutic approach has proven technically difficult and largely unsuccessful 
(McKeown and Bradner, 2014). Alternative approaches, such as inhibition of Myc-mediated 
downstream effectors, need to be investigated. Paradoxically, Myc is known to activate both 
proliferation and apoptosis, depending on the cellular context (Dang, 2012; Hoffman and 
Liebermann, 2008). However, the mechanisms that cancer cells use to escape Myc-induced 
apoptosis remain poorly understood. In this study, we found Myc activated the pro-survival 
IRE1α-XBP1 pathway in a broad spectrum of human and murine cancers, including BL, CLL, 
neuroblastoma, and hepatocellular carcinoma. In addition, our findings indicate that Myc-
transformed cancer cells rely on this pathway to sustain cell proliferation and viability. We further 
identify SCD1 as a critical IRE1α-XBP1 effector required for maintenance of ER homeostasis and 
prevention of Myc-mediated cytotoxic ER stress.  
        Disruption of ER-dependent protein folding and transport results in the accumulation of 
misfolded proteins and consequent activation of ER stress responses. Specifically, cells initiate at 
least one of three major UPR signaling pathways (PERK, IRE1, ATF6) that collectively attenuate 
protein synthesis, increase protein folding and elevate protein degradation to sustain cell survival. 
If these responses do not restore ER homeostasis, persistent UPR signaling can ultimately trigger 
apoptosis (Hetz, 2012). The UPR has recently been appreciated as a central player in tumor 
development, making it an appealing target in both solid and hematological malignancies (Clarke 
et al., 2014; Urra et al., 2016). However, several fundamental questions need to be addressed to 
rationally target the UPR and improve patient outcomes. For example, what constitute cell-
autonomous drivers of UPR in different types of cancer and how they function to integrate stress 
management must be elucidated. In addition, how to identify patients most likely to respond to 
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UPR inhibition remains unclear. In the current study, we determined that both c-Myc and N-Myc 
overexpression activates the IRE1α-XBP1 pathway through multiple molecular mechanisms. 
More importantly, this signaling pathway induces SCD1 as a critical downstream effector that 
generates unsaturated lipids to maintain ER membrane homeostasis in the face of Myc-
dependent proteotoxicity. Consistent with our results, an accompanying report (Zhao et al., 2018)  
utilizing a triple negative breast cancer model also demonstrates c-Myc regulation of IRE1α-XBP1 
signaling, and that cells with higher c-Myc expression are more sensitive to pharmacological 
IRE1α inhibition and genetic XBP1 depletion. Taken together, we identified IRE1α-XBP1 
signaling as a critical survival pathway downstream of Myc activation in multiple cancers; 
therefore, Myc activation might be utilized to predict responses to IRE1α RNase inhibitor 
treatment in patients with CLL, NB, and breast cancers. 
     Previous studies clearly show that XBP1s regulates ER-associated degradation, protein entry 
into the ER, and protein folding (Acosta-Alvear et al., 2007; Lee et al., 2003). However, to 
maintain ER homeostasis in cells with oncogene-driven protein synthesis, ER lipid membrane 
biogenesis must also be regulated to accommodate elevated protein load. For example, our 
previous studies revealed an essential role for unsaturated lipids in maintaining ER homeostasis 
and viability in cells with constitutive mTORC1 activity (Young et al., 2013). The relationship 
between the UPR and ER lipid homeostasis is underscored by data demonstrating mutant IRE1α 
and PERK proteins lacking the ability to sense unfolded proteins retain their responsiveness to 
increased lipid saturation (Volmer et al., 2013), and that SCD1 inhibition initiates ER stress in 
multiple conditions (Liu et al., 2011; Roemeling et al., 2013). In this study, we extend the model 
by demonstrating that IRE1α-XBP1 signaling itself regulates SCD1 expression (Figure 26). In the 
case of Myc-transformed cancer cells, this feedback loop is essential for cell proliferation and 
viability. Interestingly, the accompanying study describes c-Myc/XBP1s complex formation in the 
nucleus; it's possible they coordinately transcriptionally regulate SCD. Carroll et al. found that 
oncogenic Myc requires the Myc superfamily member MondoA for tumorigenesis (Carroll et al., 
2015) , and decreased lipid biosynthesis plays an important role in MondoA deficient cell death. 
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In our study, we also found IRE1α RNase inhibition decreased de novo lipogenesis, yet SCD1 
loss does not fully explain cellular responses to IRE1α inhibition. Therefore, it’s possible that 
decreased lipid biosynthesis also contributes to the observed phenotypes. Future studies will 
investigate how Myc, MondoA, and XBP1s coordinate with each other to regulate lipid 
metabolism. Our results also extend an emerging theme in which oncogenic transformation 
simultaneously induces anabolic metabolism to increase proliferation, along with homeostatic 
pathways that maintain cell viability. These include lipid and protein scavenging in RAS-
transformed tumors (Commisso et al., 2013; Kamphorst et al., 2013), autophagy downstream of 
c-Myc overexpression (Hart et al., 2012), and lipid storage downstream of HIF2α activation (Qiu 
et al., 2015).  
     The role of the IRE1α-XBP1 pathway in human cancers may be more general, as Genovese 
et al. recently demonstrated that pancreatic ductal adenocarcinoma cells exhibiting a Myc gene 
expression signature undergo an anabolic switch that increases protein metabolism and adaptive 
activation of IRE1α-mediated survival pathways (Genovese et al., 2017). Increased XBP1s levels 
are frequently associated with human multiple myeloma (Mimura et al., 2012) and disruption of 
XBP1 splicing by inhibiting IRE1α may be a promising therapeutic option in this and other 
malignancies. Finally, XBP1s promotes triple-negative breast cancer progression via HIF1α 
(Chen et al., 2014), suggesting that different oncogenic pathways may engage distinct 
downstream UPR responses, and therefore harbor non-overlapping vulnerabilities to specific 
inhibitors. 
        Our findings support the use of IRE1α RNase inhibitors as an approach to target multiple 
tumors. BL, characterized by MYC translocation and dysregulation, is a highly aggressive 
malignancy, which clinically presents as the most common pediatric cancer in specific geographic 
locations, such as equatorial Africa, Brazil, and Papua New Guinea. Although intensive 
chemotherapy can achieve long-term survival, these non-targeted agents are unsafe in older 
patients due to immune suppression and cannot be efficiently deployed in less developed regions 
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because of the need for extensive supportive care. Thus, targeted treatment strategies with fewer 
side effects are urgently needed. We provide a proof of principle of combining novel IRE1α 
inhibitors with chemotherapy drugs to decrease cytotoxicity and improve survival. In addition, 
MYCN amplification is a major prognostic factor in neuroblastoma (Huang and Weiss, 2013); 
targeting IRE1α underlying N-Myc overexpression is thus a promising strategy to treat a second 
fatal pediatric disease, where standard of care is extremely difficult and lengthy, and imposes 
significant toxicities.  
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Figure 26. Proposed model illustrating the regulation of ER stress and the IRE1α-XBP1 
pathway by c-Myc and N-Myc, and the protective role of an IRE1α-XBP1-SCD1 axis to 
counterbalance anabolic metabolism mediated by Myc overexpression. c-Myc induces ER 
stress through multiple molecular mechanism, including transcriptional regulation of ERN1, 
HSPA5, and XBP1; stabilization of IRE1α protein; and upregulation of ER protein load, thereby 
activating IRE1α RNase activity and promoting XBP1 splicing. In turn, XBP1s directly regulates 
SCD1 transcription, which is required to maintain cellular lipid metabolism homeostasis. And this 
feedback loop is essential for proliferation and viability in cells that have high either c-Myc or N-
Myc activity.  
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CHAPTER 4 Conclusions 
 
The therapeutic potential of targeting ER stress-associated machinery 
        Cancer cells continuously divide and proliferate, which can be externally challenged by 
restricted supplies of nutrients and oxygen, while internally stressed by oncogenic activities. 
Therefore, maintaining cellular homeostasis is a key for cancer cells to survive and grow. The ER 
is the principle intracellular organelle responsible for protein and lipid synthesis. Disruption of ER 
homeostasis by biochemical, physiological, and pathological stimuli results in ER stress, which 
must be overcome to survive. In response to cellular stress, a well-established signaling cascade, 
the UPR, is activated. This intricate mechanism is an important means of reestablishing cellular 
homeostasis and alleviating the inciting stress. At the same time, most normal cells are not 
subjected to stress, and the UPR pathways remain largely inactive in these cells. Therefore, the 
importance of the UPR in the maintenance of malignancy has inspired great interest in exploring 
the therapeutic potential of targeting UPR components. 
        Cancer therapeutic approaches using ER stress-associated machinery can be divided into 
two categories: 1) increasing misfolded proteins in ER to overload protein folding machinery, 
therefore inducing more severe ER stress and cell death; 2) inhibiting UPR adaptive and pro-
survival pathways, leading to failure of homeostasis restoration. For the first approach, several 
targets have been identified. For example, misfolded proteins are recognized by molecular 
chaperons and lectin-like proteins in the ERAD pathway and subsequently degraded as a part of 
an ER quality control mechanism (Ruggiano et al., 2014). As a main effector for ERAD, 
proteasome activity inhibition has been intensively studied for the treatment of cancer, such as 
Bortezomib, which has been approved for clinical use against multiple myeloma (Kouroukis et al., 
2014). Secondly, the heat shock protein 90 (HSP90) chaperone machinery is a key regulator of 
proteostasis under both physiological and stress conditions in eukaryotic cells, and upregulated in 
multiple types of cancers (Miyata et al., 2013). Consequently, HSP90 represents an ideal target 
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for the development of new anti-cancer agents (Schopf et al., 2017). Indeed, a previous study 
showed that HSP90 inhibitors 17-AAG and radicicol induce apoptosis in myeloma plasma cells 
(Davenport et al., 2007). Furthermore, Mbofung et al. recently showed that inhibition of HSP90 
with ganetespib enhances T-cell-mediated killing of patient-derived human melanoma cells by 
their autologous T cells in vitro and potentiates responses to anti-CTLA4 and anti-PD1 therapy in 
vivo (Mbofung et al., 2017). This is due to the upregulation of interferon response genes, which 
are essential for enhanced killing ability of T cells, suggesting that HSP90 inhibitors have 
immunomodulatory features (Mbofung et al., 2017).  Finally, protein folding chaperon BiP acts as 
a survival factor in solid tumors and cancer cells, and its expression is correlated with metastasis 
or late stages of tumor progression (Casas, 2017; Jamora et al., 1996; Pyrko et al., 2007). Down-
regulation of BiP by siRNA leads to decreased glioma cell growth, and lowers resistance of 
glioma cells to temozolomide. At the same time, BiP depletion sensitizes glioma cells to 5-
fluorouracil and CPT-11, suggesting that targeting BiP with conventional agents might represent a 
novel approach to eliminate residual tumor cells after surgery and increase the effectiveness of 
malignant glioma chemotherapy (Pyrko et al., 2007).  
        Another strategy is to inhibit UPR pathways. As discussed in Chapter 1, three principle 
branches of the UPR have been identified. These operate in parallel and use unique mechanisms 
of signal transduction. Each branch is defined by a class of transmembrane ER-resident signaling 
components: IRE1, PERK, and ATF6. The IRE1 branch is the most conserved and sole branch of 
the UPR in lower eukaryotes, and evolution later added the PERK and ATF6 branches to 
metazoan cells. The functions of these pathways are to attenuate protein synthesis, increase 
protein folding, and elevate protein degradative pathways. Therefore, targeting these molecules 
becomes a potential strategy for the treatment of multiple types of cancer. For instance, Hart et 
al. showed that c-Myc and N-Myc activate the PERK/eIF2α/ATF4 arm of the UPR, and inhibition 
of PERK significantly reduced c-Myc-induced autophagy, colony formation, and tumor formation 
(Dey et al., 2013; Hart et al., 2012). In addition to enabling cell survival, PERK-ATF4 signaling 
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also triggers multiple steps in the metastatic cascade (Bu and Diehl, 2016), including 
angiogenesis (Blais et al., 2006), migration (Nagelkerke et al., 2013), survival (Dey et al., 2015), 
and colonization at secondary organ sites (Bobrovnikova-Marjon et al., 2010). PERK is also 
required for the metastatic dissemination of cancer cells that have undergone an epithelial-to-
mesenchymal transition (EMT) (Feng et al., 2014). Given its critical role in driving tumor growth 
and metastatic progression, PERK has been a focus of drug discovery programs for cancer, 
which have identified several small-molecule inhibitors of this kinase. For example, GSK2656157 
is an ATP-competitive inhibitor of PERK enzyme activity with a nanomolar level of IC50, and its 
administration results in a dose-dependent slowing of the growth in multiple human tumor 
xenografts in mice (Atkins et al., 2013; Axten et al., 2013). Altered amino acid metabolism, 
decreased blood vessel density, and reduced vascular perfusion are potential mechanisms for 
the observed antitumor effect (Atkins et al., 2013; Axten et al., 2013).  At the same time, PERK 
inhibition strongly reduced the ability of EMT cells to form tumor-spheres and migrate in trans-well 
assays, and pretreatment of metastatic cancer cells with PERK inhibitor results in significantly 
diminished metastatic capacity (Feng et al., 2014), suggesting that disruption of the PERK 
pathway significantly compromises the malignant phenotype of EMT. However, while PERK 
inhibitors decrease cancer cell growth and reduce metastatic spread, they also cause rapid onset 
of pancreatic atrophy, precluding their further consideration of clinical development (Atkins et al., 
2013). In terms of ATF6, a previous study showed that knockdown of ATF6 is sufficient to 
enhance radiation induced cell death in glioblastoma cells, suggesting ATF6 as a potential 
therapeutic target to enhance the efficacy of radiation therapy (Dadey et al., 2016). In addition, 
ATF6 transcriptionally induces the expression of cancerous inhibitor of protein phosphatase 2A 
(CIP2A) and contributes to the prognosis of colon cancer (Liu et al., 2018). Furthermore, a novel 
selective ATF6 inhibitor, melatonin, induces human hepatoma cell apoptosis through COX-2 
downregulation (Bu et al., 2017).  
        IRE1α-XBP1 signaling might be the best studied UPR pathway for future treatment of 
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cancer, which plays an indispensable role in tumor growth, metastatic progression, and chemo-
resistance (Shajahan et al., 2009). XBP1 expression and activation correlates with clinical 
outcome in breast cancer (Chen et al., 2014; Davies et al., 2008), and angiogenesis in pancreatic 
adenocarcinomas (Romero-Ramirez et al., 2009): XBP1 depletion reduces blood vessel 
formation, and expression of XBP1s restores angiogenesis in IRE1α dominant-negative 
expressing cells. In mouse models of glioblastoma, IRE1α is required for upregulation of pro-
inflammatory cytokines and angiogenic factors, which contributes to tumor growth, angiogenesis, 
and invasiveness (Auf et al., 2010; Drogat et al., 2007). XBP1 is also critical in the development 
of plasma cells and is overexpressed in multiple myelomas (MMs). Several studies demonstrate 
that the IRE1α-XBP1 pathway is involved in the pathogenesis of this disease, and blockage of 
XBP1 splicing by IRE1α inhibition is a promising therapeutic option in MM (Mimura et al., 2012). 
Our study here, accompanied by a companion paper by Zhao, et al. (Zhao et al., 2018), establish 
the pro-survival functions of the IRE1α-XBP1 pathway in Myc-overexpressing cancers, including 
Burkitt’s lymphoma, neuroblastoma, and triple-negative breast cancer. These findings provide the 
evidence of inhibiting this pathway for the treatment of these types of cancer, which all together 
further expand the scenarios of using IRE1α inhibitors as a means of cancer treatment.  
Future directions 
How do c-Myc and XBP1s co-operatively regulate gene expression? 
        In Chapter 3, we show that SCD is a direct transcriptional target of XBP1s through ChIP-
qPCR analysis (Figure 16E). At the same time, the c-Myc target gene database and multiple 
previous studies establish that c-Myc also regulates SCD transcription by binding to the E-box of 
its promoter region (Wu et al., 2017; Zeller et al., 2003). This raises the possibility that c-Myc and 
XBP1s co-regulate the expression of SCD. Furthermore, ChIP-seq and motif analysis of XBP1s in 
MDA-MB-231 cells revealed statistically significant enrichment of both HIF1α and XBP1s DNA 
binding motifs, which is “CACGT”. Since the E-box sequence is “CACGTG”, it is reasonable to 
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speculate that c-Myc is a co-regulator of XBP1s in the nucleus. Therefore, it would be interesting 
to investigate interactions between c-Myc and XBP1s, as well as the genes co-regulated by these 
two proteins, to provide more insights into defining their functions in tumor initiation and 
maintenance, and assist the development of therapeutic strategies to target these pathways. 
Combining B-I09 with traditional chemotherapy for the treatment of BL? 
        BL is a highly aggressive non-Hodgkin’s lymphoma (NHL) that typically arises from germinal 
center B-lymphocytes. It is subdivided into three variants: endemic (eBL), sporadic (sBL), and 
immunodeficiency-associated (Jaffe, 2009). eBL clinically presents as the most common pediatric 
cancer in specific geographic locations, e.g. equatorial Africa, Brazil, and Papua New Guine 
(Orem et al., 2007). In these areas, the annual BL incidence has been estimated at 40-50 per 
million children younger than 18 years old, comprising approximately half of all childhood cancers 
and up to 90% of lymphoma diagnose (Orem et al., 2007). There is a low background incidence 
of sBL worldwide: In high-income countries, NHL accounts for ~7% of cancers in children 
younger than 20 years, in which ~40% are BL cases; in Western Europe and America, sBL 
accounts for 1-2% of adult lymphoma (Blum, 2004). In addition, BL is the second most common 
neoplasm in patients with HIV infection (Corti, 2016), which is a severe complication leading to 
poor outcomes. In developed countries, with intensive chemotherapy (hyper-CVAD: 
hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating 
with methotrexate and cytarabine), the 5-year survival rate of BL has increased to be >90% in 
children (Uzunova and Burke, 2016). However, these non-targeted reagents are unsafe in older 
patients due to immune suppression and cannot be efficiently deployed in less developed regions 
because of the need for extensive supportive care. Therefore, targeted treatment strategies with 
fewer side effects are thus urgently needed. 
        In our study, we demonstrate that IRE1α RNase inhibitors (like B-I09) exhibit antitumor 
effects in BL cell lines in vitro and in vivo, without showing significant side effects. Furthermore, 
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we show that B-I09 exhibits synergistic effects with Doxorubicin and Vincristine to induce 
apoptosis in both Ramos and Daudi BL cell lines (Figure 25 and Table 2), and B-I09 maintaines 
its ability to inhibit SCD1 expression in both cases.  Doxorubicin is a chemotherapy medication 
used to treat multiple types of cancers, such as breast cancer, bladder cancer, lymphoma, and 
leukemia. It has antimitotic and cytotoxic activity through a number of proposed mechanisms of 
action: it forms complexes with DNA by intercalation between base pairs, and inhibits 
topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the 
religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Vincristine is 
an antitumor vinca alkaloid isolated from Vinca rosea, which is indicated for the treatment of 
acute leukemia, malignant lymphoma, Hodgkin’s disease, and acute panmyelosis. The antitumor 
activity of Vincristine is thought to be due primarily to inhibition at metaphase through its 
interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino 
acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase 
activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Even though we have a 
detailed understanding of the mechanisms of B-I09, Doxorubicin, and Vincristine resulting in 
antitumor effects, further investigation should be performed to study mechanisms of their synergy. 
In addition, these outcomes should be confirmed in vivo, ideally with the Eλ/MYC BL mouse 
model, which will potentially reshape the current standard of care to further increase efficacy and 
decrease toxicity. 
Targeting the IRE1α-XBP1 pathway in cancer-associated myeloid cells 
        A function for the IRE1α-XBP1 pathway in cells of the immune system has been well 
established (Bettigole and Glimcher, 2015): for instance, Toll-like receptor (TLR) 2 and 4 
specifically activates this axis, which is required for optimal and sustained production of 
proinflammatory cytokines in macrophages, and XBP1 deficiency results in a much greater 
bacterial burden in mice infected with TLR2-activating human intracellular pathogen Francisela 
tularensis, suggesting a critical role of XBP1 in mammalian host defenses (Martinon et al., 2010). 
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Neutrophils infiltrating acute lung injury lesions exhibit XBP1 hyperactivation compared with lung-
resident neutrophils in naïve mice. In this setting, XBP1 was needed for optimal neutrophil 
granule release, whereas dampening XBP1 expression in neutrophils substantially alleviates 
acute lung injury (Hu et al., 2015). Furthermore, IRE1α-XBP1 signaling is required for the optimal 
differentiation of plasma cell (Reimold et al., 2001), eosinophil (Bettigole et al., 2015), and some 
dendritic cell populations (Iwakoshi et al., 2007).  
        More recently, IRE1α-XBP1 pathway functions in cancer-associated myeloid cells have 
been investigated. In ovarian cancer (OvCa), Cubillo-Ruiz et al. showed that dendritic cells in the 
OvCa microenvironment exhibit marked upregulation of ER stress response markers and robust 
XBP1 activation when compared to cells from naïve hosts, and this is induced by byproducts of 
lipid peroxidation, such as the unsaturated aldehyde 4-hydroxy-trans-2-nonenal (4-HNE) 
(Cubillos-Ruiz et al., 2015). XBP1 activation induces a triglyceride biosynthetic program in 
dendritic cells leading to abnormal lipid accumulation and subsequent inhibition of the capacity of 
these cells to support antitumor T cells. Accordingly, dendritic cell-specific XBP1 deletion restores 
their immunostimulatory activity in situ and extends host survival (Cubillos-Ruiz et al., 2015). 
Tumor-associated macrophages play critical roles during disease progression by promoting 
angiogenesis, cancer cell proliferation, invasion, and metastasis (Ostuni et al., 2015). Cysteine 
cathepsin proteases, produced by macrophages and cancer cells, modulate these processes. 
Interestingly, IL-4 synergizes with IL-6 or IL-10 to trigger IRE1α-XBP1 activation in macrophages 
through STAT6 and STAT3, a process that promoted cathepsin secretion (Yan et al., 2016), and 
pharmacological inhibition of IRE1α blocks cathepsin secretion and blunts macrophage-mediated 
cancer invasion (Yan et al., 2016). Tumor cells evade immune control by creating hostile 
microenvironments that perturb T cell metabolism and effector function (Chang et al., 2015; 
Scharping et al., 2016). A recent study shows that malignant ascites fluid obtained from patients 
with OvCa inhibit T cell glucose uptake and cause N-linked protein glycosylation defects, which 
therefore triggers IRE1α-XBP1 activation (Song et al., 2018). Consequently, XBP1 regulates the 
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abundance of glutamine carriers, thus limiting the influx of glutamine necessary to sustain 
mitochondrial respiration in T cells under glucose deprived conditions. Accordingly, mice bearing 
OvCa and lacking XBP1 in T cells demonstrate superior anti-tumor immunity, delayed malignant 
progression and increased overall survival (Song et al., 2018). These studies demonstrate a 
critical function of IRE1α-XBP1 signaling in the tumor immune microenvironment, and targeting 
this pathway seems to have a high potential to modulate tumor immunity, which inhibits tumor 
growth and progression. Since this pathway is also essential in cancer cells, it would be 
interesting to see how its manipulation could be applied in the clinics as a single agent or as a 
combinatorial treatment with immune check-point inhibitors. 
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